CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | hydroperoxide |
|
Accession: | CHEBI:35923
|
browse the term
|
Definition: | A monosubstitution product of hydrogen peroxide, HOOH. |
Synonyms: | related_synonym: | hydroperoxides |
|
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases response to substance |
ISO |
GPX1 protein results in increased susceptibility to 12-HPETE |
CTD |
PMID:11115402 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases chemical synthesis |
ISO |
GPX4 protein results in increased chemical synthesis of 12-HPETE |
CTD |
PMID:11115402 |
|
NCBI chr 7:12,516,357...12,519,154
Ensembl chr 7:12,516,352...12,519,154
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
12-HPETE inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; 12-HPETE inhibits the reaction [Sodium Salicylate results in decreased activity of PTGS2 protein] |
CTD |
PMID:12538810 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
|
G |
Cat |
catalase |
increases expression |
ISO |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of CAT protein |
CTD |
PMID:10946007 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cav1 |
caveolin 1 |
increases expression |
ISO |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of CAV1 mRNA |
CTD |
PMID:27257344 |
|
NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 protein |
CTD |
PMID:22135674 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 protein |
CTD |
PMID:22135674 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression |
EXP |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of PPARA protein |
CTD |
PMID:22135674 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
EXP |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of PPARG protein |
CTD |
PMID:22135674 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
increases expression |
ISO |
perfosfamide results in increased expression of ABL1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
|
|
G |
Actb |
actin, beta |
decreases expression |
ISO |
perfosfamide results in decreased expression of ACTB mRNA |
CTD |
PMID:19429390 |
|
NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841
|
|
G |
Agt |
angiotensinogen |
decreases response to substance |
ISO |
AGT protein results in decreased susceptibility to perfosfamide |
CTD |
PMID:11034089 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions increases response to substance |
ISO |
Acetylcysteine inhibits the reaction [perfosfamide results in increased localization of AIFM1 protein]; perfosfamide results in increased expression of and results in increased localization of AIFM1 protein AIFM1 results in increased susceptibility to perfosfamide |
CTD |
PMID:18034189 |
|
NCBI chr X:135,304,063...135,343,062
Ensembl chr X:135,304,066...135,343,087
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
affects response to substance |
ISO |
AKR1B10 protein affects the susceptibility to perfosfamide |
CTD |
PMID:18473730 |
|
NCBI chr 4:61,813,265...61,830,371
Ensembl chr 4:61,771,970...61,828,657
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases response to substance |
ISO |
ALDH1A1 protein results in decreased susceptibility to perfosfamide |
CTD |
PMID:8662658 PMID:16614850 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
decreases response to substance |
ISO |
ALDH1A2 protein results in decreased susceptibility to perfosfamide |
CTD |
PMID:22079344 |
|
NCBI chr 8:77,640,234...77,719,488
Ensembl chr 8:77,640,222...77,719,489
|
|
G |
Aldh1b1 |
aldehyde dehydrogenase 1 family, member B1 |
affects response to substance |
ISO |
ALDH1B1 protein affects the susceptibility to perfosfamide |
CTD |
PMID:18473730 |
|
NCBI chr 5:61,382,351...61,387,359
Ensembl chr 5:61,382,351...61,387,358
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases response to substance |
ISO |
ALDH2 protein results in decreased susceptibility to perfosfamide |
CTD |
PMID:22079344 |
|
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
decreases response to substance |
ISO |
ALDH3A1 protein results in decreased susceptibility to perfosfamide |
CTD |
PMID:16614850 |
|
NCBI chr10:47,490,168...47,499,855
Ensembl chr10:47,490,153...47,499,876
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
decreases expression |
EXP |
perfosfamide results in decreased expression of APEX1 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr15:27,849,943...27,852,083
Ensembl chr15:27,849,979...27,852,082
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions affects folding increases expression |
ISO |
Acetylcysteine inhibits the reaction [perfosfamide affects the folding of BAX protein]; Acetylcysteine inhibits the reaction [perfosfamide results in increased localization of BAX]; perfosfamide results in increased expression of and results in increased localization of BAX perfosfamide results in increased expression of BAX protein |
CTD |
PMID:16488414 PMID:18034189 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
ISO |
perfosfamide results in increased expression of BBC3 mRNA |
CTD |
PMID:17068108 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Bmpr1b |
bone morphogenetic protein receptor type 1B |
decreases expression |
ISO |
perfosfamide results in decreased expression of BMPR1B mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 2:247,392,195...247,662,026
Ensembl chr 2:247,403,920...247,446,882
|
|
G |
C1d |
C1D nuclear receptor corepressor |
increases expression |
ISO |
perfosfamide results in increased expression of C1D mRNA |
CTD |
PMID:19429390 |
|
NCBI chr14:100,415,645...100,427,878
Ensembl chr14:100,415,668...100,427,260
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
perfosfamide results in increased activity of CASP3 perfosfamide promotes the reaction [TNF results in increased activity of CASP3 protein] |
CTD |
PMID:16488414 PMID:17434952 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
perfosfamide results in increased activity of CASP9 protein |
CTD |
PMID:16488414 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
perfosfamide results in increased expression of CDKN1A perfosfamide results in increased expression of CDKN1A mRNA; perfosfamide results in increased expression of CDKN1A protein |
CTD |
PMID:17068108 PMID:18034189 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
decreases expression |
ISO |
perfosfamide results in decreased expression of CXCL9 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr14:17,228,832...17,233,743
Ensembl chr14:17,228,856...17,234,712
|
|
G |
E2f1 |
E2F transcription factor 1 |
increases expression |
ISO |
perfosfamide results in increased expression of E2F1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
ISO |
perfosfamide results in decreased expression of EGR1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Endog |
endonuclease G |
increases response to substance multiple interactions |
ISO |
ENDOG results in increased susceptibility to perfosfamide Acetylcysteine inhibits the reaction [perfosfamide results in increased localization of ENDOG protein]; perfosfamide results in increased expression of and results in increased localization of ENDOG protein |
CTD |
PMID:18034189 |
|
NCBI chr 3:8,741,833...8,744,414
Ensembl chr 3:8,741,766...8,744,592
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
increases expression |
ISO |
perfosfamide results in increased expression of EPAS1 protein |
CTD |
PMID:23251655 |
|
NCBI chr 6:10,306,508...10,385,239
Ensembl chr 6:10,306,405...10,387,265
|
|
G |
Epha6 |
Eph receptor A6 |
decreases expression |
ISO |
perfosfamide results in decreased expression of EPHA6 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr11:41,867,607...42,843,800
|
|
G |
Eya1 |
EYA transcriptional coactivator and phosphatase 1 |
decreases expression |
ISO |
perfosfamide results in decreased expression of EYA1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 5:4,275,728...4,495,525
Ensembl chr 5:4,373,626...4,513,142
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
perfosfamide results in increased expression of FASLG mRNA; perfosfamide results in increased expression of FASLG protein |
CTD |
PMID:14760101 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Foxf1 |
forkhead box F1 |
affects expression |
ISO |
perfosfamide affects the expression of FOXF1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr19:53,012,306...53,016,100
Ensembl chr19:53,012,332...53,016,086
|
|
G |
Gjc1 |
gap junction protein, gamma 1 |
increases expression |
ISO |
perfosfamide results in increased expression of GJC1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr10:90,781,408...90,912,440
Ensembl chr10:90,781,402...90,912,287
|
|
G |
Gli2 |
GLI family zinc finger 2 |
decreases expression |
ISO |
perfosfamide results in decreased expression of GLI2 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr13:34,829,021...35,049,172
Ensembl chr13:34,829,139...35,048,444
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
increases expression |
ISO |
perfosfamide results in increased expression of HES1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr11:74,312,837...74,315,249
Ensembl chr11:74,312,806...74,315,248
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
perfosfamide results in increased expression of HIF1A mRNA; perfosfamide results in increased expression of HIF1A protein |
CTD |
PMID:19429390 PMID:23251655 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hoxa11 |
homeobox A11 |
decreases expression |
ISO |
perfosfamide results in decreased expression of HOXA11 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 4:82,296,888...82,301,419
Ensembl chr 4:82,298,152...82,300,503 Ensembl chr 4:82,298,152...82,300,503
|
|
G |
Hoxa13 |
homeo box A13 |
increases expression |
ISO |
perfosfamide results in increased expression of HOXA13 mRNA |
CTD |
PMID:19429390 |
|
Ensembl chr 4:82,228,017...82,229,397
|
|
G |
Hoxd10 |
homeo box D10 |
increases expression |
ISO |
perfosfamide results in increased expression of HOXD10 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 3:61,614,133...61,617,342
Ensembl chr 3:61,613,774...61,617,367
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
decreases expression |
ISO |
perfosfamide results in decreased expression of HRAS mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
|
|
G |
Kl |
Klotho |
decreases expression |
ISO |
perfosfamide results in decreased expression of KL mRNA |
CTD |
PMID:19429390 |
|
NCBI chr12:942,974...987,206
Ensembl chr12:943,006...987,551
|
|
G |
Lig3 |
DNA ligase 3 |
decreases expression |
EXP |
perfosfamide results in decreased expression of LIG3 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr10:70,134,734...70,158,051
Ensembl chr10:70,134,729...70,158,055
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
ISO |
perfosfamide results in increased expression of MDM2 |
CTD |
PMID:18034189 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases expression |
EXP |
perfosfamide results in decreased expression of MGMT mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
|
|
G |
Mlh1 |
mutL homolog 1 |
decreases expression |
EXP |
perfosfamide results in decreased expression of MLH1 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 8:119,486,655...119,523,716
Ensembl chr 8:119,486,691...119,523,964
|
|
G |
Mpg |
N-methylpurine-DNA glycosylase |
decreases expression |
EXP |
perfosfamide results in decreased expression of MPG mRNA |
CTD |
PMID:11754170 |
|
NCBI chr10:15,661,768...15,667,995
Ensembl chr10:15,661,608...15,668,022
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
decreases expression |
EXP |
perfosfamide results in decreased expression of MRE11A mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 8:13,304,355...13,350,329
Ensembl chr 8:13,305,152...13,352,489
|
|
G |
Myo1b |
myosin Ib |
increases expression |
ISO |
perfosfamide results in increased expression of MYO1B mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 9:54,706,005...54,766,054
Ensembl chr 9:54,558,202...54,766,054
|
|
G |
Myog |
myogenin |
increases expression |
ISO |
perfosfamide results in increased expression of MYOG mRNA |
CTD |
PMID:19429390 |
|
NCBI chr13:51,126,459...51,129,048
Ensembl chr13:51,126,459...51,129,048
|
|
G |
Ndn |
necdin, MAGE family member |
increases expression |
ISO |
perfosfamide results in increased expression of NDN mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 1:122,981,755...122,983,354
Ensembl chr 1:122,981,755...122,983,351
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
decreases expression |
ISO |
perfosfamide results in decreased expression of ODC1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 6:42,852,529...42,859,142
Ensembl chr 6:42,852,683...42,859,927
|
|
G |
Pea15 |
proliferation and apoptosis adaptor protein 15 |
decreases expression |
ISO |
perfosfamide results in decreased expression of PEA15 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr13:90,579,844...90,589,466
Ensembl chr13:90,579,846...90,589,466
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
perfosfamide results in increased expression of PMAIP1 mRNA |
CTD |
PMID:17068108 |
|
NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
|
|
G |
Pms1 |
PMS1 homolog 1, mismatch repair system component |
decreases expression |
EXP |
perfosfamide results in decreased expression of PMS1 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 9:53,120,656...53,206,520
Ensembl chr 9:53,120,656...53,206,516
|
|
G |
Pms2 |
PMS1 homolog 2, mismatch repair system component |
decreases expression |
EXP |
perfosfamide results in decreased expression of PMS2 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr12:12,714,394...12,738,654
Ensembl chr12:12,714,394...12,738,641
|
|
G |
Polb |
DNA polymerase beta |
decreases expression |
EXP |
perfosfamide results in decreased expression of POLB mRNA |
CTD |
PMID:11754170 |
|
NCBI chr16:74,237,001...74,260,272
Ensembl chr16:74,237,001...74,260,271
|
|
G |
Pold1 |
DNA polymerase delta 1, catalytic subunit |
decreases expression |
ISO |
perfosfamide results in decreased expression of POLD1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 1:100,538,066...100,554,105
Ensembl chr 1:100,537,900...100,554,488
|
|
G |
Rad21 |
RAD21 cohesin complex component |
decreases expression |
ISO |
perfosfamide results in decreased expression of RAD21 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 7:91,511,755...91,538,673
Ensembl chr 7:91,511,756...91,538,673
|
|
G |
Rad50 |
RAD50 double strand break repair protein |
decreases expression |
EXP |
perfosfamide results in decreased expression of RAD50 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr10:39,002,130...39,054,042
Ensembl chr10:39,001,498...39,054,142
|
|
G |
Rad51 |
RAD51 recombinase |
decreases expression |
EXP |
perfosfamide results in decreased expression of RAD51 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 3:110,918,240...110,942,920
Ensembl chr 3:110,918,243...110,942,917
|
|
G |
Sdf4 |
stromal cell derived factor 4 |
decreases expression |
ISO |
perfosfamide results in decreased expression of SDF4 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 5:173,425,922...173,444,478
Ensembl chr 5:173,425,907...173,444,620
|
|
G |
Sfrp2 |
secreted frizzled-related protein 2 |
decreases expression |
ISO |
perfosfamide results in decreased expression of SFRP2 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 2:182,723,732...182,731,277
Ensembl chr 2:182,723,854...182,731,764
|
|
G |
Slc30a4 |
solute carrier family 30 member 4 |
decreases expression |
ISO |
perfosfamide results in decreased expression of SLC30A4 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 3:114,805,919...114,828,154
Ensembl chr 3:114,805,922...114,828,154
|
|
G |
Smad1 |
SMAD family member 1 |
decreases expression |
ISO |
perfosfamide results in decreased expression of SMAD1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr19:32,182,942...32,248,694
Ensembl chr19:32,188,267...32,248,684
|
|
G |
Tap1 |
transporter 1, ATP binding cassette subfamily B member |
affects response to substance |
ISO |
TAP1 protein affects the susceptibility to perfosfamide |
CTD |
PMID:18473730 |
|
NCBI chr20:3,979,302...3,989,669
Ensembl chr20:3,979,035...3,989,669
|
|
G |
Tcf12 |
transcription factor 12 |
increases expression |
ISO |
perfosfamide results in increased expression of TCF12 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 8:78,343,634...78,657,738
Ensembl chr 8:78,345,754...78,655,856
|
|
G |
Terc |
telomerase RNA component |
decreases expression |
ISO |
perfosfamide results in decreased expression of TERC mRNA |
CTD |
PMID:24571982 |
|
NCBI chr 2:116,432,723...116,433,110
Ensembl chr 2:116,432,691...116,433,110
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases expression |
ISO |
perfosfamide results in decreased expression of TERT mRNA |
CTD |
PMID:24571982 |
|
NCBI chr 1:32,250,876...32,275,330
Ensembl chr 1:32,251,714...32,272,476
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
perfosfamide promotes the reaction [TNF results in increased activity of CASP3 protein] |
CTD |
PMID:16488414 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [perfosfamide results in increased expression of TP53] perfosfamide results in increased expression of and results in increased phosphorylation of and results in increased activity of TRP53 protein |
CTD |
PMID:17068108 PMID:18034189 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Trim27 |
tripartite motif-containing 27 |
decreases expression |
ISO |
perfosfamide results in decreased expression of TRIM27 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr17:45,613,863...45,626,212
Ensembl chr17:45,613,864...45,626,212
|
|
G |
Ttf1 |
transcription termination factor 1 |
decreases expression |
ISO |
perfosfamide results in decreased expression of TTF1 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 3:7,635,630...7,660,153
Ensembl chr 3:7,635,933...7,660,673
|
|
G |
Ubb |
ubiquitin B |
decreases expression |
ISO |
perfosfamide results in decreased expression of UBB mRNA |
CTD |
PMID:19429390 |
|
NCBI chr10:48,880,231...48,881,896
Ensembl chr10:48,881,049...48,881,881
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
perfosfamide results in increased expression of VEGFA mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vim |
vimentin |
decreases expression |
ISO |
perfosfamide results in decreased expression of VIM mRNA |
CTD |
PMID:19429390 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
G |
Wnt11 |
Wnt family member 11 |
increases expression |
ISO |
perfosfamide results in increased expression of WNT11 mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 1:163,794,136...163,813,756
Ensembl chr 1:163,797,660...163,813,756
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
decreases expression |
EXP |
perfosfamide results in decreased expression of XRCC1 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 1:81,412,635...81,441,680
Ensembl chr 1:81,413,353...81,441,678
|
|
G |
Xrcc5 |
X-ray repair cross complementing 5 |
decreases expression |
EXP |
perfosfamide results in decreased expression of XRCC5 mRNA |
CTD |
PMID:11754170 |
|
NCBI chr 9:79,659,275...79,748,050
Ensembl chr 9:79,659,251...79,748,078
|
|
G |
Ywhaz |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta |
decreases expression |
ISO |
perfosfamide results in decreased expression of YWHAZ mRNA |
CTD |
PMID:19429390 |
|
NCBI chr 7:75,573,553...75,598,295
Ensembl chr 7:75,574,967...75,597,276
|
|
|
G |
Cat |
catalase |
decreases activity increases activity multiple interactions |
ISO EXP |
cumene hydroperoxide results in decreased activity of CAT protein cumene hydroperoxide results in increased activity of CAT protein Iron promotes the reaction [cumene hydroperoxide results in decreased activity of CAT protein]; Iron-Dextran Complex promotes the reaction [cumene hydroperoxide results in decreased activity of CAT protein] |
CTD |
PMID:12065085 PMID:12423650 PMID:16928893 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
affects oxidation |
EXP |
CYP2B1 protein affects the oxidation of cumene hydroperoxide |
CTD |
PMID:17478480 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
affects oxidation |
EXP |
CYP2B6 protein affects the oxidation of cumene hydroperoxide |
CTD |
PMID:17478480 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
affects oxidation |
ISO |
CYP2C19 protein affects the oxidation of cumene hydroperoxide |
CTD |
PMID:17478480 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
affects oxidation |
ISO |
CYP2C8 protein affects the oxidation of cumene hydroperoxide |
CTD |
PMID:17478480 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp2d1 |
cytochrome P450, family 2, subfamily d, polypeptide 1 |
affects oxidation |
EXP |
CYP2D1 protein affects the oxidation of cumene hydroperoxide |
CTD |
PMID:17478480 |
|
NCBI chr 7:123,625,641...123,630,045
Ensembl chr 7:123,625,590...123,638,765
|
|
G |
Cyp2s1 |
cytochrome P450, family 2, subfamily s, polypeptide 1 |
multiple interactions |
ISO |
[[CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of benzo(a)pyrene 7,8-dihydrodiol] which results in increased abundance of benzo(a)pyrene-7,8,9,10-tetrol; [[CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of Benzo(a)pyrene] which results in increased abundance of benzo(a)pyrene-1,6-quinone; [[CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of Benzo(a)pyrene] which results in increased abundance of benzo(a)pyrene-3,6-quinone; [[CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of Benzo(a)pyrene] which results in increased abundance of benzo(a)pyrene-6,12-quinone; [CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of 9,10-dihydrobenzo(a)pyrene; [CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of 9,10-Dimethyl-1,2-benzanthracene; [CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of Aflatoxin B1; [CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of Benzo(a)pyrene; [CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of benzo(a)pyrene 7,8-dihydrodiol; [CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of Tretinoin |
CTD |
PMID:19713358 |
|
NCBI chr 1:82,595,211...82,610,350
Ensembl chr 1:82,595,211...82,610,350
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
multiple interactions decreases expression |
EXP |
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [cumene hydroperoxide results in decreased expression of EEF2 protein]; Vitamin E analog inhibits the reaction [cumene hydroperoxide results in decreased expression of EEF2 protein] cumene hydroperoxide results in decreased expression of EEF2; cumene hydroperoxide results in decreased expression of EEF2 protein |
CTD |
PMID:16469450 PMID:17510559 PMID:19447174 |
|
NCBI chr 7:11,401,501...11,406,771
Ensembl chr 7:11,401,501...11,406,771
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
multiple interactions |
ISO |
cumene hydroperoxide results in increased phosphorylation of and results in increased activity of FGFR2 protein |
CTD |
PMID:12717419 |
|
NCBI chr 1:200,590,951...200,696,946
Ensembl chr 1:200,590,953...200,696,928
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
increases activity |
EXP |
cumene hydroperoxide results in increased activity of G6PD protein |
CTD |
PMID:16928893 |
|
NCBI chr X:156,274,800...156,293,935
Ensembl chr X:156,274,800...156,293,926
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of GAPDH protein |
CTD |
PMID:11295360 |
|
NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of GCLC mRNA |
CTD |
PMID:30547568 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of GCLM mRNA |
CTD |
PMID:30547568 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases response to substance increases metabolic processing increases reduction |
ISO |
GPX1 protein results in decreased susceptibility to cumene hydroperoxide GPX1 protein results in increased metabolism of cumene hydroperoxide GPX1 protein results in increased reduction of cumene hydroperoxide |
CTD |
PMID:1740415 PMID:1939125 PMID:8428933 PMID:9126277 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases reduction |
ISO |
GPX2 protein results in increased reduction of cumene hydroperoxide |
CTD |
PMID:8428933 |
|
NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
decreases response to substance |
ISO |
GPX4 results in decreased susceptibility to cumene hydroperoxide |
CTD |
PMID:18206984 |
|
NCBI chr 7:12,516,357...12,519,154
Ensembl chr 7:12,516,352...12,519,154
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases activity |
EXP |
cumene hydroperoxide results in decreased activity of GSR protein |
CTD |
PMID:16928893 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
increases metabolic processing |
ISO |
GSTA1 protein results in increased metabolism of cumene hydroperoxide |
CTD |
PMID:1985777 |
|
NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
decreases metabolic processing affects metabolic processing decreases response to substance increases metabolic processing |
ISO EXP |
GSTA2 protein polymorphism results in decreased metabolism of cumene hydroperoxide GSTA3 protein affects the metabolism of cumene hydroperoxide GSTA3 protein results in decreased susceptibility to cumene hydroperoxide GSTA2 protein results in increased metabolism of cumene hydroperoxide |
CTD |
PMID:1740415 PMID:2768223 PMID:3138230 PMID:15077012 PMID:15128049 |
|
NCBI chr 8:85,640,081...85,645,621
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
increases glutathionylation |
ISO |
GSTA3 protein results in increased glutathionylation of cumene hydroperoxide |
CTD |
PMID:21876218 |
|
NCBI chr 9:27,357,490...27,417,023
Ensembl chr 9:27,402,381...27,417,023
|
|
G |
Gstm3 |
glutathione S-transferase mu 3 |
decreases metabolic processing increases metabolic processing |
ISO |
GSTM3 protein polymorphism results in decreased metabolism of cumene hydroperoxide GSTM3 protein polymorphism results in increased metabolism of cumene hydroperoxide |
CTD |
PMID:15247628 |
|
NCBI chr 2:210,685,204...210,688,273
Ensembl chr 2:210,685,197...210,688,272
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
decreases metabolic processing increases metabolic processing |
ISO |
GSTM3 protein polymorphism results in decreased metabolism of cumene hydroperoxide GSTM3 protein polymorphism results in increased metabolism of cumene hydroperoxide |
CTD |
PMID:15247628 |
|
NCBI chr 2:210,685,338...210,688,133
Ensembl chr 2:210,685,197...210,688,272
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases metabolic processing |
ISO |
GSTP1 protein results in increased metabolism of cumene hydroperoxide |
CTD |
PMID:2747627 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
affects oxidation affects metabolic processing |
ISO |
GSTT1 protein affects the oxidation of cumene hydroperoxide GSTT1 protein affects the metabolism of cumene hydroperoxide |
CTD |
PMID:9854036 PMID:19664997 |
|
NCBI chr20:13,799,102...13,816,527
Ensembl chr20:13,799,102...13,816,526
|
|
G |
Gstt2 |
glutathione S-transferase, theta 2 |
affects metabolic processing |
EXP |
GSTT2 protein affects the metabolism of cumene hydroperoxide |
CTD |
PMID:2114406 |
|
NCBI chr20:13,760,810...13,764,481
Ensembl chr20:13,760,810...13,764,475
|
|
G |
Gstz1 |
glutathione S-transferase zeta 1 |
affects metabolic processing |
ISO |
GSTZ1 protein affects the metabolism of cumene hydroperoxide |
CTD |
PMID:9396740 |
|
NCBI chr 6:111,176,798...111,187,246
Ensembl chr 6:111,176,798...111,187,244
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions decreases uptake increases secretion |
ISO |
alpha-Tocopherol inhibits the reaction [cumene hydroperoxide results in decreased uptake of GUSB protein]; alpha-Tocopherol inhibits the reaction [cumene hydroperoxide results in increased secretion of GUSB protein] |
CTD |
PMID:19135433 |
|
NCBI chr12:30,202,066...30,215,583
Ensembl chr12:30,198,822...30,227,771
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of HMOX1 mRNA |
CTD |
PMID:30547568 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of HSPB1 protein |
CTD |
PMID:11295360 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Idh1 |
isocitrate dehydrogenase (NADP(+)) 1 |
increases activity |
EXP |
cumene hydroperoxide results in increased activity of IDH1 protein |
CTD |
PMID:16928893 |
|
NCBI chr 9:71,882,108...71,911,645
Ensembl chr 9:71,882,105...71,900,044
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion |
ISO |
alpha-Tocopherol inhibits the reaction [cumene hydroperoxide results in increased secretion of IL1B protein] |
CTD |
PMID:19135433 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to cumene hydroperoxide; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to cumene hydroperoxide] |
CTD |
PMID:19608619 |
|
NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
|
|
G |
Mb |
myoglobin |
affects metabolic processing |
ISO |
MB protein mutant form affects the metabolism of cumene hydroperoxide |
CTD |
PMID:8855949 |
|
NCBI chr 7:118,101,633...118,108,864
Ensembl chr 7:118,101,634...118,108,864
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases response to substance |
EXP |
MGST1 results in decreased susceptibility to cumene hydroperoxide |
CTD |
PMID:17306223 |
|
NCBI chr 4:172,119,382...172,134,609
Ensembl chr 4:172,119,331...172,134,607
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene co-treated with cumene hydroperoxide] results in increased activity of MPO protein |
CTD |
PMID:14972014 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
increases response to substance affects response to substance multiple interactions |
ISO |
NFE2L2 gene mutant form results in increased susceptibility to cumene hydroperoxide [NFE2L2 affects the susceptibility to sulforafan] which affects the susceptibility to cumene hydroperoxide Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforafan results in decreased susceptibility to cumene hydroperoxide]]; NFE2L2 protein promotes the reaction [sulforafan results in decreased susceptibility to cumene hydroperoxide] [KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to cumene hydroperoxide; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to cumene hydroperoxide] |
CTD |
PMID:19303893 PMID:19608619 PMID:20932822 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO |
alpha-Tocopherol inhibits the reaction [cumene hydroperoxide results in increased expression of NOS2 protein] |
CTD |
PMID:19135433 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of NQO1 mRNA |
CTD |
PMID:30547568 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
increases activity multiple interactions |
ISO |
cumene hydroperoxide results in increased activity of ODC1 protein Iron promotes the reaction [cumene hydroperoxide results in increased activity of ODC1 protein]; Iron-Dextran Complex promotes the reaction [cumene hydroperoxide results in increased activity of ODC1 protein] |
CTD |
PMID:12065085 |
|
NCBI chr 6:42,852,529...42,859,142
Ensembl chr 6:42,852,683...42,859,927
|
|
G |
Ppia |
peptidylprolyl isomerase A |
decreases response to substance |
EXP |
PPIA protein results in decreased susceptibility to cumene hydroperoxide |
CTD |
PMID:17011206 |
|
NCBI chr14:86,673,775...86,677,443
Ensembl chr14:86,673,775...86,677,443
|
|
G |
Prdx1 |
peroxiredoxin 1 |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of PRDX1 protein |
CTD |
PMID:11295360 |
|
NCBI chr 5:135,536,413...135,551,986
Ensembl chr 5:135,536,413...135,551,990
|
|
G |
Prdx2 |
peroxiredoxin 2 |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of PRDX2 protein |
CTD |
PMID:11295360 |
|
NCBI chr19:26,084,816...26,090,095
Ensembl chr19:26,084,903...26,090,094
|
|
G |
Prdx6 |
peroxiredoxin 6 |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of PRDX6 protein |
CTD |
PMID:11295360 |
|
NCBI chr13:79,077,567...79,088,113
Ensembl chr13:79,077,033...79,088,127
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
cumene hydroperoxide results in increased expression of PTGS2 protein [cumene hydroperoxide results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [cumene hydroperoxide results in increased expression of PTGS2 protein] |
CTD |
PMID:14972014 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Sord |
sorbitol dehydrogenase |
increases activity |
EXP |
cumene hydroperoxide results in increased activity of SORD protein |
CTD |
PMID:16928893 |
|
NCBI chr 3:114,176,127...114,207,368
Ensembl chr 3:114,176,309...114,207,366
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
cumene hydroperoxide results in increased expression of TGFB1 mRNA |
CTD |
PMID:8148055 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion |
ISO |
alpha-Tocopherol inhibits the reaction [cumene hydroperoxide results in increased secretion of TNF protein] |
CTD |
PMID:19135433 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions increases lipidation |
ISO |
Ascorbic Acid promotes the reaction [linoleic acid hydroperoxide results in increased lipidation of AGT protein modified form] |
CTD |
PMID:26111765 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Cygb |
cytoglobin |
increases metabolic processing |
EXP |
CYGB protein results in increased metabolism of linoleic acid hydroperoxide |
CTD |
PMID:11320098 |
|
NCBI chr10:105,618,325...105,628,091
Ensembl chr10:105,618,326...105,628,091
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases reduction |
ISO |
GPX1 protein results in increased reduction of linoleic acid hydroperoxide |
CTD |
PMID:8428933 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases reduction |
ISO |
GPX2 protein results in increased reduction of linoleic acid hydroperoxide |
CTD |
PMID:8428933 |
|
NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ABCA1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions affects localization |
EXP |
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [tert-Butylhydroperoxide affects the localization of ABCB11 protein]; Bilirubin analog inhibits the reaction [tert-Butylhydroperoxide affects the localization of and results in decreased activity of ABCB11 protein]; Bucladesine inhibits the reaction [tert-Butylhydroperoxide affects the localization of ABCB11 protein]; tert-Butylhydroperoxide affects the localization of and results in decreased activity of ABCB11 protein |
CTD |
PMID:16452108 PMID:24306262 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ABCB1A mRNA |
CTD |
PMID:14729362 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression multiple interactions |
ISO EXP |
tert-Butylhydroperoxide results in decreased expression of ABCC2 mRNA Bilirubin analog inhibits the reaction [tert-Butylhydroperoxide affects the localization of and results in decreased activity of ABCC2 protein]; tert-Butylhydroperoxide affects the localization of and results in decreased activity of ABCC2 protein |
CTD |
PMID:22956110 PMID:24306262 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcd1 |
ATP binding cassette subfamily D member 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ABCD1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr X:157,073,860...157,095,652
Ensembl chr X:157,072,736...157,095,274
|
|
G |
Abhd17a |
abhydrolase domain containing 17A, depalmitoylase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ABHD17A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:11,992,543...12,000,978
Ensembl chr 7:11,992,543...11,998,973
|
|
G |
Ablim1 |
actin-binding LIM protein 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ABLIM1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:277,853,877...278,043,096
|
|
G |
Abr |
ABR activator of RhoGEF and GTPase |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ABR mRNA |
CTD |
PMID:15003993 |
|
NCBI chr10:64,565,121...64,657,079
Ensembl chr10:64,567,268...64,657,089
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
increases expression multiple interactions decreases expression |
ISO EXP |
tert-Butylhydroperoxide results in increased expression of ACADS mRNA acadesine inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of ACADS mRNA]; acadesine inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of and results in decreased activity of ACADS protein]; Fenofibrate inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of ACADS mRNA]; Fenofibrate inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of and results in decreased activity of ACADS protein]; tert-Butylhydroperoxide results in decreased expression of and results in decreased activity of ACADS protein |
CTD |
PMID:15003993 PMID:26989860 |
|
NCBI chr12:47,254,503...47,263,747
Ensembl chr12:47,254,484...47,263,747
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions increases secretion increases expression |
EXP |
Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide inhibits the reaction [tert-Butylhydroperoxide results in increased secretion of ACHE protein] tert-Butylhydroperoxide results in increased expression of ACHE mRNA alternative form |
CTD |
PMID:16903848 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ACKR3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:97,355,881...97,367,455
Ensembl chr 9:97,355,924...97,367,445
|
|
G |
Aco1 |
aconitase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ACO1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:56,425,076...56,481,218
Ensembl chr 5:56,425,024...56,481,218
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ACOT1 mRNA |
CTD |
PMID:14729362 |
|
NCBI chr 6:107,485,088...107,493,082
Ensembl chr 6:107,485,249...107,493,798
|
|
G |
Acot7 |
acyl-CoA thioesterase 7 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ACOT7 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 5:169,357,582...169,450,215
Ensembl chr 5:169,357,517...169,450,219
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ACSL3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:84,569,601...84,593,565
Ensembl chr 9:84,569,597...84,593,565
|
|
G |
Actb |
actin, beta |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ACTB mRNA |
CTD |
PMID:12419474 |
|
NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841
|
|
G |
Actg2 |
actin gamma 2, smooth muscle |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ACTG2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:115,215,160...115,239,746
Ensembl chr 4:115,215,060...115,239,723
|
|
G |
Actn1 |
actinin, alpha 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ACTN1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:103,376,557...103,470,497
Ensembl chr 6:103,375,799...103,470,555
|
|
G |
Actr3 |
actin related protein 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ACTR3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:41,695,520...41,738,622
Ensembl chr13:41,695,183...41,738,658
|
|
G |
Actr3b |
actin related protein 3B |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ACTR3B mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:5,644,287...5,672,708
Ensembl chr 4:5,644,260...5,672,708
|
|
G |
Acy3 |
aminoacylase 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ACY3 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:219,233,712...219,237,103
Ensembl chr 1:219,233,750...219,237,098
|
|
G |
Acyp1 |
acylphosphatase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ACYP1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:109,097,065...109,110,266
Ensembl chr 6:109,097,065...109,104,050
|
|
G |
Adam19 |
ADAM metallopeptidase domain 19 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ADAM19 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:31,146,107...31,240,582
Ensembl chr10:31,146,107...31,240,582
|
|
G |
Adam8 |
ADAM metallopeptidase domain 8 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ADAM8 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:212,317,510...212,332,895
Ensembl chr 1:212,317,848...212,330,349
|
|
G |
Adam9 |
ADAM metallopeptidase domain 9 |
multiple interactions affects expression increases expression |
ISO |
[rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ADAM9 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ADAM9 mRNA]; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ADAM9 mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ADAM9 mRNA] tert-Butylhydroperoxide affects the expression of ADAM9 mRNA |
CTD |
PMID:20847119 PMID:23410634 |
|
NCBI chr16:71,810,377...71,887,926
Ensembl chr16:71,810,377...71,887,926
|
|
G |
Adar |
adenosine deaminase, RNA-specific |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ADAR mRNA |
CTD |
PMID:14729362 PMID:15003993 |
|
NCBI chr 2:189,045,551...189,085,448
Ensembl chr 2:189,062,443...189,083,236
|
|
G |
Adat1 |
adenosine deaminase, tRNA-specific 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ADAT1 mRNA |
CTD |
PMID:15963989 |
|
NCBI chr19:44,172,496...44,212,147
Ensembl chr19:44,187,331...44,211,208
|
|
G |
Adcy3 |
adenylate cyclase 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ADCY3 mRNA |
CTD |
PMID:12414654 |
|
NCBI chr 6:28,570,941...28,648,848
Ensembl chr 6:28,571,351...28,650,148
|
|
G |
Adcy9 |
adenylate cyclase 9 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ADCY9 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:11,392,698...11,515,406
Ensembl chr10:11,392,625...11,512,600
|
|
G |
Add2 |
adducin 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ADD2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:117,691,294...117,887,556
Ensembl chr 4:117,743,710...117,882,464
|
|
G |
Add3 |
adducin 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ADD3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:273,854,195...273,961,982
Ensembl chr 1:273,854,248...273,961,982
|
|
G |
Adgrg6 |
adhesion G protein-coupled receptor G6 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ADGRG6 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:8,593,342...8,751,540
Ensembl chr 1:8,593,075...8,751,198
|
|
G |
Adh7 |
alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ADH7 mRNA |
CTD |
PMID:14729362 PMID:15336504 |
|
NCBI chr 2:243,500,540...243,516,865
Ensembl chr 2:243,502,073...243,516,532
|
|
G |
Adipor2 |
adiponectin receptor 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ADIPOR2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:151,412,135...151,480,108
Ensembl chr 4:151,414,684...151,428,894
|
|
G |
Adm |
adrenomedullin |
multiple interactions increases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ADM mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ADM mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ADM mRNA; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ADM mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ADM mRNA] |
CTD |
PMID:14729362 PMID:15003993 PMID:15336504 PMID:20847119 PMID:29432895 |
|
NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259
|
|
G |
Adora1 |
adenosine A1 receptor |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ADORA1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr13:51,042,111...51,076,913
Ensembl chr13:51,042,248...51,076,852
|
|
G |
Adora2b |
adenosine A2B receptor |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ADORA2B mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:48,569,563...48,586,366
Ensembl chr10:48,569,555...48,586,365
|
|
G |
Agk |
acylglycerol kinase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AGK mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:68,483,345...68,561,518
Ensembl chr 4:68,483,320...68,560,801
|
|
G |
Ago2 |
argonaute RISC catalytic component 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AGO2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:114,339,607...114,377,277
Ensembl chr 7:114,339,434...114,380,613
|
|
G |
Agpat1 |
1-acylglycerol-3-phosphate O-acyltransferase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AGPAT1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr20:4,369,399...4,378,272
Ensembl chr20:4,369,178...4,378,269
|
|
G |
Ahsa1 |
activator of Hsp90 ATPase activity 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AHSA1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:111,296,168...111,304,224
Ensembl chr 6:111,296,417...111,304,224
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions increases expression |
ISO |
resveratrol inhibits the reaction [tert-Butylhydroperoxide results in increased expression of AIFM1 protein] |
CTD |
PMID:25522270 |
|
NCBI chr X:135,304,063...135,343,062
Ensembl chr X:135,304,066...135,343,087
|
|
G |
Aip |
aryl-hydrocarbon receptor-interacting protein |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AIP mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:219,361,859...219,373,924
Ensembl chr 1:219,361,860...219,374,014
|
|
G |
Ajuba |
ajuba LIM protein |
multiple interactions decreases expression |
ISO |
[Pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of AJUBA mRNA; [Rosiglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of AJUBA mRNA; [Troglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of AJUBA mRNA; Troglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of AJUBA mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr15:33,208,210...33,218,456
Ensembl chr15:33,208,216...33,218,456
|
|
G |
Ak2 |
adenylate kinase 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AK2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:147,185,474...147,204,050
Ensembl chr 5:147,185,474...147,204,050
|
|
G |
Ak4 |
adenylate kinase 4 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AK4 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 5:120,250,318...120,309,153
Ensembl chr 5:120,250,616...120,305,897
|
|
G |
Akap12 |
A-kinase anchoring protein 12 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of AKAP12 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 1:40,816,130...40,906,582
Ensembl chr 1:40,816,107...40,906,581
|
|
G |
Akap9 |
A-kinase anchoring protein 9 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AKAP9 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:27,195,346...27,331,582
Ensembl chr 4:27,195,346...27,331,582
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AKR1B10 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 4:61,813,265...61,830,371
Ensembl chr 4:61,771,970...61,828,657
|
|
G |
Akr1b8 |
aldo-keto reductase family 1, member B8 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AKR1B8 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 4:61,772,064...61,784,637
Ensembl chr 4:61,771,970...61,828,657
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AKR1C2 mRNA |
CTD |
PMID:12414654 PMID:15336504 PMID:23410634 |
|
NCBI chr17:69,388,337...69,435,160
Ensembl chr17:69,388,335...69,404,341
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
tert-Butylhydroperoxide results in decreased phosphorylation of AKT1 protein 3,4-dihydroxyphenyllactic acid inhibits the reaction [tert-Butylhydroperoxide results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:29128606 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
decreases expression increases methylation |
ISO |
tert-Butylhydroperoxide results in decreased expression of AKT2 mRNA tert-Butylhydroperoxide results in increased methylation of AKT2 gene |
CTD |
PMID:27509014 |
|
NCBI chr 1:84,400,939...84,451,223
Ensembl chr 1:84,411,726...84,450,162
|
|
G |
Alad |
aminolevulinate dehydratase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ALAD mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:78,368,867...78,379,206
Ensembl chr 5:78,368,867...78,379,346
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ALAS1 protein |
CTD |
PMID:21659532 |
|
NCBI chr 8:114,927,704...114,941,038
Ensembl chr 8:114,927,722...114,940,177
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression affects expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ALDH1A1 mRNA tert-Butylhydroperoxide affects the expression of ALDH1A1 mRNA |
CTD |
PMID:15336504 PMID:23410634 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ALDH1A3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:127,302,920...127,337,828
Ensembl chr 1:127,301,128...127,337,882
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
increases expression decreases response to substance |
ISO |
tert-Butylhydroperoxide results in increased expression of ALDH2 mRNA ALDH2 protein results in decreased susceptibility to tert-Butylhydroperoxide |
CTD |
PMID:14729362 PMID:15003993 PMID:15336504 |
|
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
|
|
G |
Aldh3a2 |
aldehyde dehydrogenase 3 family, member A2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ALDH3A2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:47,525,486...47,546,535
Ensembl chr10:47,525,493...47,546,345
|
|
G |
Aldh4a1 |
aldehyde dehydrogenase 4 family, member A1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ALDH4A1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:158,090,238...158,115,725
Ensembl chr 5:158,042,587...158,135,733
|
|
G |
Aldh6a1 |
aldehyde dehydrogenase 6 family, member A1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ALDH6A1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:108,146,552...108,167,185
Ensembl chr 6:108,146,582...108,167,185
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase 7 family, member A1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ALDH7A1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr18:51,619,007...51,651,267
Ensembl chr18:51,619,007...51,651,267
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ALDOA mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:198,228,387...198,233,988
Ensembl chr 1:198,228,387...198,233,588
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ALOX5 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:148,398,004...148,446,308
Ensembl chr 4:148,398,892...148,446,303
|
|
G |
Amd1 |
adenosylmethionine decarboxylase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AMD1 mRNA |
CTD |
PMID:27509014 |
|
NCBI chr20:45,384,000...45,399,694
Ensembl chr20:45,384,000...45,399,694
|
|
G |
Amigo2 |
adhesion molecule with Ig like domain 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AMIGO2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:138,704,124...138,707,221
Ensembl chr 7:138,704,126...138,707,221
|
|
G |
Amotl2 |
angiomotin like 2 |
multiple interactions decreases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of AMOTL2 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of AMOTL2 mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of AMOTL2 mRNA; tert-Butylhydroperoxide promotes the reaction [PPARG protein binds to AMOTL2 promoter]; troglitazone inhibits the reaction [tert-Butylhydroperoxide promotes the reaction [PPARG protein binds to AMOTL2 promoter]]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of AMOTL2 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 8:111,210,261...111,226,217
Ensembl chr 8:111,209,908...111,226,226
|
|
G |
Ampd3 |
adenosine monophosphate deaminase 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AMPD3 mRNA |
CTD |
PMID:15003993 PMID:15336504 |
|
NCBI chr 1:175,585,301...175,630,479
Ensembl chr 1:175,586,097...175,630,467
|
|
G |
Amph |
amphiphysin |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AMPH mRNA |
CTD |
PMID:12419474 PMID:15336504 |
|
NCBI chr17:48,304,324...48,562,838
Ensembl chr17:48,304,322...48,562,905
|
|
G |
Anapc5 |
anaphase-promoting complex subunit 5 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ANAPC5 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:39,209,134...39,242,696
Ensembl chr12:39,209,129...39,242,690
|
|
G |
Angptl2 |
angiopoietin-like 2 |
multiple interactions increases expression |
ISO |
[Pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ANGPTL2 mRNA; [Rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ANGPTL2 mRNA; Pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ANGPTL2 mRNA]; Troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ANGPTL2 mRNA] |
CTD |
PMID:15003993 PMID:20847119 |
|
NCBI chr 3:12,262,822...12,292,665
Ensembl chr 3:12,262,822...12,292,663
|
|
G |
Angptl7 |
angiopoietin like 7 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ANGPTL7 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:165,311,794...165,318,361
Ensembl chr 5:165,312,130...165,316,652
|
|
G |
Ankmy2 |
ankyrin repeat and MYND domain containing 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ANKMY2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:55,646,905...55,689,223
Ensembl chr 6:55,648,021...55,689,218
|
|
G |
Ankra2 |
ankyrin repeat family A member 2 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of ANKRA2 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr X:82,407,601...82,418,229
Ensembl chr X:82,407,598...82,418,425
|
|
G |
Ankrd10 |
ankyrin repeat domain 10 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ANKRD10 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:83,205,898...83,229,147
Ensembl chr16:83,206,004...83,228,194
|
|
G |
Ankrd2 |
ankyrin repeat domain 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ANKRD2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:261,281,859...261,291,307
Ensembl chr 1:261,281,543...261,291,394
|
|
G |
Ankrd37 |
ankyrin repeat domain 37 |
multiple interactions increases expression |
ISO |
[Pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ANKRD37 mRNA; [Rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ANKRD37 mRNA; [Troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ANKRD37 mRNA; Pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ANKRD37 mRNA]; Rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ANKRD37 mRNA]; Troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ANKRD37 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr16:49,463,016...49,465,905
Ensembl chr16:49,462,889...49,465,888
|
|
G |
Ankrd6 |
ankyrin repeat domain 6 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ANKRD6 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:48,052,610...48,167,568
Ensembl chr 5:48,052,401...48,194,294
|
|
G |
Anp32a |
acidic nuclear phosphoprotein 32 family member A |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ANP32A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:67,295,578...67,333,075
Ensembl chr 8:67,295,727...67,333,247
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ANPEP mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:141,561,364...141,604,249
Ensembl chr 1:141,561,334...141,604,273
|
|
G |
Anxa4 |
annexin A4 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ANXA4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:118,538,775...118,595,591
Ensembl chr 4:118,538,777...118,595,580
|
|
G |
Anxa8 |
annexin A8 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ANXA8 mRNA |
CTD |
PMID:14729362 PMID:15003993 |
|
NCBI chr16:10,417,174...10,432,388
Ensembl chr16:10,417,185...10,432,393
|
|
G |
Aox1 |
aldehyde oxidase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AOX1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870
|
|
G |
Ap3b1 |
adaptor related protein complex 3 subunit beta 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AP3B1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:24,022,815...24,227,522
Ensembl chr 2:24,024,791...24,226,224
|
|
G |
Ap3d1 |
adaptor related protein complex 3 subunit delta 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AP3D1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:11,838,639...11,873,992
Ensembl chr 7:11,838,639...11,873,984
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression multiple interactions |
ISO EXP |
tert-Butylhydroperoxide results in increased expression of APAF1 protein Acetylcysteine inhibits the reaction [tert-Butylhydroperoxide results in increased expression of APAF1 protein] |
CTD |
PMID:15877105 PMID:17419000 |
|
NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
|
|
G |
Aplp2 |
amyloid beta precursor like protein 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of APLP2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:32,298,526...32,328,821
Ensembl chr 8:32,298,532...32,328,839
|
|
G |
Apoa5 |
apolipoprotein A5 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of APOA5 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 8:50,559,079...50,561,720
Ensembl chr 8:50,559,126...50,561,736
|
|
G |
Apoe |
apolipoprotein E |
increases expression affects localization |
ISO EXP |
tert-Butylhydroperoxide results in increased expression of APOE mRNA tert-Butylhydroperoxide affects the localization of APOE protein |
CTD |
PMID:15336504 PMID:19720132 |
|
NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
|
|
G |
Apold1 |
apolipoprotein L domain containing 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of APOLD1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:168,752,142...168,755,024
Ensembl chr 4:168,752,133...168,755,023
|
|
G |
App |
amyloid beta precursor protein |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of APP mRNA |
CTD |
PMID:12419474 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of APPL1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:2,560,103...2,602,035
Ensembl chr16:2,563,520...2,602,103
|
|
G |
Appl2 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of APPL2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:26,256,179...26,306,128
Ensembl chr 7:26,256,459...26,306,126
|
|
G |
Aqp1 |
aquaporin 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AQP1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:85,551,503...85,563,683
Ensembl chr 4:85,551,502...85,569,360
|
|
G |
Aqp4 |
aquaporin 4 |
multiple interactions |
EXP |
tert-Butylhydroperoxide results in increased expression of and affects the localization of AQP4 protein |
CTD |
PMID:20648640 |
|
NCBI chr18:6,766,009...6,782,757
Ensembl chr18:6,765,945...6,782,996
|
|
G |
Aqr |
aquarius intron-binding spliceosomal factor |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AQR mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:105,570,399...105,640,431
Ensembl chr 3:105,570,292...105,640,463
|
|
G |
Areg |
amphiregulin |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AREG mRNA |
CTD |
PMID:12414654 |
|
NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179
|
|
G |
Arf6 |
ADP-ribosylation factor 6 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ARF6 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:91,697,109...91,698,257
Ensembl chr 6:91,697,109...91,698,255
|
|
G |
Arg2 |
arginase 2 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of ARG2 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 6:102,311,097...102,338,406
Ensembl chr 6:102,311,116...102,338,520
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ARHGDIA mRNA |
CTD |
PMID:12419474 |
|
NCBI chr10:109,754,012...109,757,506
Ensembl chr10:109,754,004...109,757,550
|
|
G |
Arhgef10 |
Rho guanine nucleotide exchange factor 10 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ARHGEF10 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:79,725,629...79,817,065
Ensembl chr16:79,725,643...79,793,619
|
|
G |
Arhgef7 |
Rho guanine nucleotide exchange factor 7 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ARHGEF7 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:83,006,732...83,117,065
Ensembl chr16:83,006,718...83,132,785
|
|
G |
Arid3a |
AT-rich interaction domain 3A |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of ARID3A mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 7:12,573,604...12,602,407
Ensembl chr 7:12,574,198...12,601,674
|
|
G |
Arl6ip1 |
ADP-ribosylation factor like GTPase 6 interacting protein 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ARL6IP1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:187,770,160...187,779,675
Ensembl chr 1:187,770,160...187,779,675
|
|
G |
Arl6ip5 |
ADP-ribosylation factor like GTPase 6 interacting protein 5 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ARL6IP5 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:129,574,363...129,598,240
Ensembl chr 4:129,574,264...129,598,915
|
|
G |
Arntl2 |
aryl hydrocarbon receptor nuclear translocator-like 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ARNTL2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:181,103,774...181,158,415
Ensembl chr 4:181,103,774...181,214,994
|
|
G |
Arpc1a |
actin related protein 2/3 complex, subunit 1A |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ARPC1A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:11,272,609...11,294,084
Ensembl chr12:11,272,609...11,294,058
|
|
G |
Asf1a |
anti-silencing function 1A histone chaperone |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ASF1A mRNA |
CTD |
PMID:23410634 |
|
NCBI chr20:34,894,419...34,909,265
Ensembl chr20:34,894,419...34,909,265
|
|
G |
Asf1b |
anti-silencing function 1B histone chaperone |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ASF1B mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:25,077,918...25,092,491
Ensembl chr19:25,077,918...25,092,491
|
|
G |
Asph |
aspartate-beta-hydroxylase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ASPH mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:22,577,680...22,799,333
Ensembl chr 5:22,577,675...22,799,349
|
|
G |
Aspscr1 |
ASPSCR1 tether for SLC2A4, UBX domain containing |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ASPSCR1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:109,851,407...109,889,339
Ensembl chr10:109,851,854...109,888,623
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
decreases expression |
ISO EXP |
tert-Butylhydroperoxide results in decreased expression of ASS1 mRNA; tert-Butylhydroperoxide results in decreased expression of ASS1 protein |
CTD |
PMID:15336504 PMID:24394546 |
|
NCBI chr 3:10,327,411...10,375,847
Ensembl chr 3:10,327,414...10,375,826
|
|
G |
Asxl1 |
ASXL transcriptional regulator 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ASXL1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:148,832,231...148,902,356
Ensembl chr 3:148,837,814...148,900,452
|
|
G |
Atad2 |
ATPase family, AAA domain containing 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ATAD2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:97,984,754...98,027,379
Ensembl chr 7:97,984,862...98,026,052
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions decreases expression increases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ATF3 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ATF3 mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ATF3 mRNA; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ATF3 mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ATF3 mRNA] tert-Butylhydroperoxide results in decreased expression of ATF3 mRNA |
CTD |
PMID:12414654 PMID:20196124 PMID:20847119 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Atg4b |
autophagy related 4B, cysteine peptidase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ATG4B mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:100,888,457...100,920,123
Ensembl chr 9:100,888,501...100,918,637
|
|
G |
Atg5 |
autophagy related 5 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ATG5 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
|
|
G |
Atp13a3 |
ATPase 13A3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ATP13A3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr11:73,936,750...73,963,852
Ensembl chr11:73,936,750...73,963,852
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ATP2A2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:39,553,903...39,603,326
Ensembl chr12:39,553,903...39,603,326
|
|
G |
Atp2b1 |
ATPase plasma membrane Ca2+ transporting 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ATP2B1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:41,114,606...41,223,138
Ensembl chr 7:41,114,697...41,220,579
|
|
G |
Atp6v1a |
ATPase H+ transporting V1 subunit A |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ATP6V1A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr11:61,531,386...61,584,634
Ensembl chr11:61,531,416...61,584,634
|
|
G |
Atp6v1c1 |
ATPase H+ transporting V1 subunit C1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ATP6V1C1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:77,678,853...77,716,658
Ensembl chr 7:77,678,968...77,716,408
|
|
G |
Atr |
ATR serine/threonine kinase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ATR mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 8:103,673,578...103,770,886
Ensembl chr 8:103,673,411...103,770,947
|
|
G |
Atxn1 |
ataxin 1 |
affects localization decreases expression multiple interactions |
ISO |
tert-Butylhydroperoxide affects the localization of ATXN1 protein mutant form tert-Butylhydroperoxide results in decreased expression of ATXN1 mRNA Acetylcysteine inhibits the reaction [tert-Butylhydroperoxide affects the localization of ATXN1 protein mutant form]; Buthionine Sulfoximine promotes the reaction [tert-Butylhydroperoxide affects the localization of ATXN1 protein mutant form] |
CTD |
PMID:12893416 PMID:15336504 |
|
NCBI chr17:19,160,986...19,533,814
Ensembl chr17:19,249,952...19,533,814
|
|
G |
Atxn3 |
ataxin 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ATXN3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:125,817,420...125,853,461
Ensembl chr 6:125,819,640...125,853,461
|
|
G |
Aurka |
aurora kinase A |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of AURKA mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 3:170,364,177...170,380,278
Ensembl chr 3:170,364,181...170,378,210
|
|
G |
Aurkb |
aurora kinase B |
decreases expression increases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AURKB mRNA tert-Butylhydroperoxide results in increased expression of AURKB mRNA |
CTD |
PMID:12414654 PMID:29432895 |
|
NCBI chr10:55,625,860...55,632,399
Ensembl chr10:55,626,741...55,634,991
|
|
G |
Auts2 |
activator of transcription and developmental regulator AUTS2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AUTS2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:27,155,362...28,252,752
Ensembl chr12:28,212,333...28,251,816
|
|
G |
Azin1 |
antizyme inhibitor 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of AZIN1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:77,345,646...77,372,398
Ensembl chr 7:77,345,646...77,372,398
|
|
G |
Babam1 |
BRISC and BRCA1 A complex member 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BABAM1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:19,792,720...19,798,886
Ensembl chr16:19,792,838...19,798,894
|
|
G |
Babam2 |
BRISC and BRCA1 A complex member 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BABAM2 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 6:25,666,654...26,135,888
Ensembl chr 6:25,666,655...26,051,229
|
|
G |
Bace2 |
beta-secretase 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BACE2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr11:37,798,397...37,880,624
Ensembl chr11:37,798,370...37,880,821
|
|
G |
Bad |
BCL2-associated agonist of cell death |
decreases expression increases expression multiple interactions |
ISO EXP |
tert-Butylhydroperoxide results in decreased expression of BAD mRNA tert-Butylhydroperoxide results in increased expression of BAD protein Curcumin inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BAD protein] |
CTD |
PMID:12419474 PMID:15569404 PMID:17419000 |
|
NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BAK1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr20:5,609,620...5,618,899
Ensembl chr20:5,609,625...5,618,260
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
decreases expression affects expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BAMBI mRNA tert-Butylhydroperoxide affects the expression of BAMBI mRNA |
CTD |
PMID:15336504 PMID:23410634 |
|
NCBI chr17:56,905,419...56,909,675
Ensembl chr17:56,905,112...56,909,992
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions affects localization increases expression decreases expression |
ISO EXP |
1-(3,4-dihydroxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BAX protein]; hyperoside inhibits the reaction [tert-Butylhydroperoxide affects the localization of BAX protein]; LY96 protein affects the reaction [tert-Butylhydroperoxide results in increased expression of BAX protein]; LY96 protein promotes the reaction [tert-Butylhydroperoxide results in increased expression of BAX protein]; Peptides inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BAX protein] acadesine inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BAX protein]; Curcumin inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BAX protein]; Fenofibrate inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BAX protein] tert-Butylhydroperoxide results in decreased expression of BAX mRNA |
CTD |
PMID:12419474 PMID:15569404 PMID:17419000 PMID:18552516 PMID:20510348 PMID:23994092 PMID:25522270 PMID:26989860 PMID:28063877 PMID:29111459 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Baz1b |
bromodomain adjacent to zinc finger domain, 1B |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BAZ1B mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:24,478,882...24,536,851
Ensembl chr12:24,478,898...24,537,313
|
|
G |
Bbln |
bublin coiled coil protein |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BBLN mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:11,408,076...11,410,907
Ensembl chr 3:11,408,348...11,410,732
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression affects localization |
EXP ISO |
acadesine inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; Curcumin inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; Fenofibrate inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; Plant Extracts inhibits the reaction [tert-Butylhydroperoxide affects the localization of BCL2 protein]; Plant Extracts inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; Silymarin inhibits the reaction [tert-Butylhydroperoxide affects the localization of BCL2 protein]; Silymarin inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein] 1-(3,4-dihydroxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; 3,4-dihydroxyphenyllactic acid inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; Genistein inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; LY96 protein affects the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; Peptides inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; Plant Extracts inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; Quercetin inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein] tert-Butylhydroperoxide results in decreased expression of BCL2 mRNA; tert-Butylhydroperoxide results in decreased expression of BCL2 protein |
CTD |
PMID:12782109 PMID:15288519 PMID:15569404 PMID:17419000 PMID:19772912 PMID:20510348 PMID:22659508 PMID:23994092 PMID:25522270 PMID:26989860 PMID:27050144 PMID:29111459 PMID:29128606 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression |
EXP ISO |
Curcumin inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2L1 protein] tert-Butylhydroperoxide results in decreased expression of BCL2L1 mRNA; tert-Butylhydroperoxide results in decreased expression of BCL2L1 protein Plant Extracts inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2L1 protein]; puag-haad inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2L1 protein]; Quercetin inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2L1 protein] |
CTD |
PMID:12419474 PMID:15569404 PMID:26102008 PMID:27050144 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bcl2l13 |
BCL2 like 13 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BCL2L13 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:153,385,200...153,438,096
Ensembl chr 4:153,385,205...153,436,660
|
|
G |
Bdh1 |
3-hydroxybutyrate dehydrogenase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BDH1 mRNA |
CTD |
PMID:29432895 |
|
NCBI chr11:72,577,547...72,619,435
Ensembl chr11:72,578,533...72,614,176
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BDNF mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Bex4 |
brain expressed, X-linked 4 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BEX4 mRNA |
CTD |
PMID:15336504 |
|
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
increases methylation decreases expression |
ISO |
tert-Butylhydroperoxide results in increased methylation of BHMT gene tert-Butylhydroperoxide results in decreased expression of BHMT mRNA |
CTD |
PMID:27509014 |
|
NCBI chr 2:23,236,573...23,256,158
Ensembl chr 2:23,236,575...23,256,158
|
|
G |
Bicd1 |
BICD cargo adaptor 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BICD1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:184,018,845...184,167,628
Ensembl chr 4:184,019,087...184,165,540
|
|
G |
Bik |
BCL2-interacting killer |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BIK mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 7:124,390,924...124,410,449
Ensembl chr 7:124,391,432...124,410,447
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BIRC5 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Bles03 |
basophilic leukemia expressed protein BLES03 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of C11ORF68 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:220,806,563...220,808,817
Ensembl chr 1:220,806,473...220,808,804
|
|
G |
Blnk |
B-cell linker |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BLNK mRNA |
CTD |
PMID:14729362 |
|
NCBI chr 1:260,187,023...260,254,490
Ensembl chr 1:260,186,967...260,254,600
|
|
G |
Bmerb1 |
bMERB domain containing 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BMERB1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:3,411,380...3,570,689
Ensembl chr10:3,411,380...3,570,688
|
|
G |
Bmp1 |
bone morphogenetic protein 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BMP1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr15:52,166,401...52,210,786
Ensembl chr15:52,166,401...52,210,746
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BMP4 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr15:20,776,060...20,791,013
Ensembl chr15:20,776,054...20,822,740
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
decreases expression increases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BNIP3 mRNA tert-Butylhydroperoxide results in increased expression of BNIP3 mRNA |
CTD |
PMID:12419474 PMID:15003993 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Bora |
bora, aurora kinase A activator |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BORA mRNA |
CTD |
PMID:15336504 |
|
NCBI chr15:83,442,217...83,463,737
Ensembl chr15:83,442,144...83,463,717
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BRAF mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 4:67,389,331...67,520,549
Ensembl chr 4:67,396,192...67,520,356
|
|
G |
Brd3 |
bromodomain containing 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BRD3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:5,995,204...6,054,467
Ensembl chr 3:5,997,315...6,054,483
|
|
G |
Bscl2 |
BSCL2 lipid droplet biogenesis associated, seipin |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BSCL2 mRNA |
CTD |
PMID:22003191 |
|
NCBI chr 1:225,035,956...225,046,137
Ensembl chr 1:225,037,737...225,046,040
|
|
G |
Bst1 |
bone marrow stromal cell antigen 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BST1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr14:71,798,218...71,814,540
Ensembl chr14:71,798,651...71,814,523
|
|
G |
Bst2 |
bone marrow stromal cell antigen 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BST2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:19,938,781...19,942,353
Ensembl chr16:19,938,784...19,942,353
|
|
G |
Btbd2 |
BTB domain containing 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BTBD2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:11,929,859...11,943,559
Ensembl chr 7:11,930,135...11,942,799
|
|
G |
Btd |
biotinidase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BTD mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:7,758,192...7,791,301
Ensembl chr16:7,758,996...7,791,243
|
|
G |
Btf3 |
basic transcription factor 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BTF3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:28,417,316...28,424,436
Ensembl chr 2:28,417,579...28,423,762
|
|
G |
Btg1 |
BTG anti-proliferation factor 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BTG1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 7:37,812,831...37,815,088
Ensembl chr 7:37,812,831...37,815,088
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of BTG2 mRNA |
CTD |
PMID:12414654 PMID:21382384 |
|
NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of BUB1 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 3:120,373,604...120,404,910
Ensembl chr 3:120,373,604...120,404,910
|
|
G |
Bud23 |
BUD23, rRNA methyltransferase and ribosome maturation factor |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of BUD23 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:24,669,626...24,680,833
Ensembl chr12:24,669,449...24,680,818
|
|
G |
Bzw1 |
basic leucine zipper and W2 domains 1 |
multiple interactions increases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of BZW1 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of BZW1 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BZW1 mRNA]; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BZW1 mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BZW1 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 9:65,279,675...65,293,471
Ensembl chr 9:65,279,675...65,291,651
|
|
G |
C1r |
complement C1r |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of C1R mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:157,126,060...157,136,825
Ensembl chr 4:157,125,998...157,136,829
|
|
G |
C2cd2 |
C2 calcium-dependent domain containing 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of C2CD2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr11:38,354,746...38,420,133
Ensembl chr11:38,357,424...38,420,119
|
|
G |
C5 |
complement C5 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of C5 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:14,049,993...14,113,931 NCBI chr 3:14,206,466...14,229,141
Ensembl chr 3:14,049,995...14,229,080
|
|
G |
Ca8 |
carbonic anhydrase 8 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CA8 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:21,249,018...21,345,810
Ensembl chr 5:21,249,020...21,345,810
|
|
G |
Cadm1 |
cell adhesion molecule 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CADM1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:51,858,906...52,200,591
Ensembl chr 8:52,127,399...52,189,722
|
|
G |
Cadm4 |
cell adhesion molecule 4 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CADM4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:81,365,200...81,369,841
Ensembl chr 1:81,365,138...81,370,109
|
|
G |
Calhm2 |
calcium homeostasis modulator family member 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CALHM2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:266,908,367...266,914,093
Ensembl chr 1:266,908,369...266,914,093
|
|
G |
Calm1 |
calmodulin 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CALM1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:124,217,241...124,225,292
Ensembl chr 6:124,217,241...124,225,292
|
|
G |
Calm3 |
calmodulin 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CALM3 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:78,844,520...78,851,628
Ensembl chr 1:78,843,080...78,851,719
|
|
G |
Calml4 |
calmodulin-like 4 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CALML4 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 8:67,753,279...67,765,359
Ensembl chr 8:67,753,279...67,765,358
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CALR mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666
|
|
G |
Calu |
calumenin |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CALU mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:56,625,611...56,653,112
Ensembl chr 4:56,625,561...56,653,111
|
|
G |
Camk2n1 |
calcium/calmodulin-dependent protein kinase II inhibitor 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CAMK2N1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:156,876,706...156,878,486
Ensembl chr 5:156,876,706...156,878,486
|
|
G |
Camlg |
calcium modulating ligand |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CAML mRNA |
CTD |
PMID:14729362 |
|
NCBI chr17:9,523,792...9,534,683
Ensembl chr17:9,523,795...9,534,653
|
|
G |
Camp |
cathelicidin antimicrobial peptide |
decreases expression |
EXP |
tert-Butylhydroperoxide results in decreased expression of CAMP mRNA |
CTD |
PMID:22659508 |
|
NCBI chr 8:117,930,557...117,932,371
Ensembl chr 8:117,930,546...117,932,518
|
|
G |
Cand1 |
cullin-associated and neddylation-dissociated 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CAND1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:62,124,362...62,162,451
Ensembl chr 7:62,124,362...62,162,453
|
|
G |
Capn1 |
calpain 1 |
increases response to substance increases expression |
ISO |
CAPN1 protein results in increased susceptibility to tert-Butylhydroperoxide tert-Butylhydroperoxide results in increased expression of CAPN1 mRNA |
CTD |
PMID:12842444 PMID:15003993 |
|
NCBI chr 1:221,346,081...221,370,965
Ensembl chr 1:221,346,066...221,370,322
|
|
G |
Capn2 |
calpain 2 |
decreases expression affects expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CAPN2 mRNA tert-Butylhydroperoxide affects the expression of CAPN2 mRNA |
CTD |
PMID:12419474 PMID:23410634 |
|
NCBI chr13:100,878,649...100,928,811
Ensembl chr13:100,878,650...100,928,811
|
|
G |
Capn5 |
calpain 5 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CAPN5 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:163,073,134...163,129,736
Ensembl chr 1:163,073,124...163,129,641
|
|
G |
Capn7 |
calpain 7 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CAPN7 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:7,435,541...7,472,483
Ensembl chr16:7,435,634...7,471,807
|
|
G |
Capns1 |
calpain, small subunit 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CAPNS1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 1:91,058,528...91,064,880
|
|
G |
Caprin2 |
caprin family member 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CAPRIN2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:183,304,993...183,374,195
Ensembl chr 4:183,305,813...183,374,195
|
|
G |
Cars2 |
cysteinyl-tRNA synthetase 2, mitochondrial |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CARS2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:83,288,613...83,325,706
Ensembl chr16:83,288,664...83,325,699
|
|
G |
Cask |
calcium/calmodulin dependent serine protein kinase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CASK mRNA |
CTD |
PMID:12419474 |
|
NCBI chr X:9,815,652...10,156,155
Ensembl chr X:9,815,652...10,156,155
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage decreases expression increases activity increases expression |
ISO EXP |
1-(3,4-dihydroxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CASP3 protein modified form]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]]; acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]; Drugs, Chinese Herbal inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CASP3 protein]; GPX4 protein inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]; KN 93 inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]]; LY96 protein promotes the reaction [tert-Butylhydroperoxide results in increased expression of CASP3 protein modified form]; MCL1 protein inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]]; nectandrin-B inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP3 protein]; PAFAH2 protein inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]; puag-haad inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CASP3 protein]; rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]; zinc protoporphyrin inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]] acadesine inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP3 protein]; Curcumin inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP3 protein]; Fenofibrate inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]; Silymarin inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein] caffeoylquinic acid analog inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]; Catechin inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP3 protein]; Drugs, Chinese Herbal inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]; tert-Butylhydroperoxide results in increased expression of and results in increased cleavage of CASP3 protein tert-Butylhydroperoxide results in increased expression of CASP3 protein; tert-Butylhydroperoxide results in increased expression of CASP3 protein modified form |
CTD |
PMID:12406338 PMID:15496407 PMID:15569404 PMID:15611089 PMID:15877105 PMID:16753784 PMID:17419000 PMID:19647727 PMID:19772912 PMID:20510348 PMID:20847119 PMID:26102008 PMID:26989860 PMID:27511913 PMID:28025122 PMID:28063877 PMID:28733231 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases cleavage |
ISO |
Plant Extracts inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP7 protein]; Quercetin inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP7 protein] |
CTD |
PMID:27050144 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp9 |
caspase 9 |
increases cleavage multiple interactions increases expression |
EXP ISO |
tert-Butylhydroperoxide results in increased cleavage of CASP9 protein Plant Extracts inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP9 protein]; Quercetin inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP9 protein] tert-Butylhydroperoxide results in increased expression of CASP9 protein Plant Extracts inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP9 protein]; Silymarin inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP9 protein] |
CTD |
PMID:15877105 PMID:17003459 PMID:19772912 PMID:20510348 PMID:27050144 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cast |
calpastatin |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CAST mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:1,452,111...1,561,669
Ensembl chr 2:1,452,116...1,561,464
|
|
G |
Cat |
catalase |
affects response to substance increases activity decreases activity multiple interactions increases expression decreases expression decreases response to substance |
ISO EXP |
CAT protein affects the susceptibility to tert-Butylhydroperoxide tert-Butylhydroperoxide results in increased activity of CAT protein tert-Butylhydroperoxide results in decreased activity of CAT protein CAT protein results in increased susceptibility to [tert-Butylhydroperoxide co-treated with Desoxycorticosterone co-treated with tempol] tert-Butylhydroperoxide results in increased expression of CAT mRNA CAT protein inhibits the reaction [tert-Butylhydroperoxide results in increased expression of FOS mRNA]; CAT protein inhibits the reaction [tert-Butylhydroperoxide results in increased expression of JUN mRNA]; Catechin inhibits the reaction [tert-Butylhydroperoxide results in decreased activity of CAT protein] tert-Butylhydroperoxide results in decreased expression of CAT mRNA; tert-Butylhydroperoxide results in decreased expression of CAT protein Oleanolic Acid inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CAT protein]; Quercetin inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CAT protein] CAT protein results in decreased susceptibility to tert-Butylhydroperoxide |
CTD |
PMID:10754530 PMID:11178967 PMID:12423650 PMID:12628296 PMID:12646410 PMID:14729362 PMID:15003993 PMID:15105052 PMID:15207383 PMID:15336504 PMID:15849717 PMID:16126241 PMID:16753784 PMID:16928893 PMID:17003459 PMID:20100471 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cav1 |
caveolin 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CAV1 mRNA |
CTD |
PMID:15963989 |
|
NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
|
|
G |
Cav2 |
caveolin 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CAV2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:44,573,264...44,580,640
Ensembl chr 4:44,573,264...44,580,638
|
|
G |
Cavin2 |
caveolae associated protein 2 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of CAVIN2 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 9:55,244,136...55,256,153
Ensembl chr 9:55,243,255...55,256,340
|
|
G |
Cbfb |
core-binding factor subunit beta |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CBFB mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:37,127,508...37,171,075
Ensembl chr19:37,127,508...37,171,069
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CBR3 mRNA |
CTD |
PMID:21382384 |
|
NCBI chr11:33,909,417...33,917,674
Ensembl chr11:33,909,439...33,917,674
|
|
G |
Cbs |
cystathionine beta synthase |
decreases expression increases methylation |
ISO |
tert-Butylhydroperoxide results in decreased expression of CBS mRNA tert-Butylhydroperoxide results in increased methylation of CBS gene |
CTD |
PMID:15336504 PMID:27509014 |
|
NCBI chr20:10,361,987...10,386,663
Ensembl chr20:10,361,988...10,386,751
|
|
G |
Ccdc25 |
coiled-coil domain containing 25 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CCDC25 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr15:42,522,108...42,555,318
Ensembl chr15:42,522,108...42,553,398
|
|
G |
Ccdc86 |
coiled-coil domain containing 86 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CCDC86 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:226,996,435...227,002,016
Ensembl chr 1:226,996,237...227,002,139
|
|
G |
Ccdc93 |
coiled-coil domain containing 93 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CCDC93 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:37,400,455...37,473,973
Ensembl chr13:37,400,476...37,468,840
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCL2 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCL2 mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCL2 mRNA; tert-Butylhydroperoxide promotes the reaction [PPARG protein binds to CCL2 promoter]; troglitazone inhibits the reaction [tert-Butylhydroperoxide promotes the reaction [PPARG protein binds to CCL2 promoter]]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CCL2 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CCL5 mRNA |
CTD |
PMID:14729362 PMID:15003993 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Ccn1 |
cellular communication network factor 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CCN1 mRNA |
CTD |
PMID:12414654 PMID:15336504 |
|
NCBI chr 2:251,529,354...251,532,312
Ensembl chr 2:251,529,354...251,532,312
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions affects expression decreases expression |
ISO |
[Pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCN2 mRNA; [Rosiglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCN2 mRNA; [Troglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCN2 mRNA; Pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CCN2 mRNA]; Troglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CCN2 mRNA] tert-Butylhydroperoxide affects the expression of CCN2 mRNA |
CTD |
PMID:20847119 PMID:23410634 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccn3 |
cellular communication network factor 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CCN3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:94,375,134...94,382,154
Ensembl chr 7:94,375,020...94,383,024
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression affects expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CCNA2 mRNA tert-Butylhydroperoxide affects the expression of CCNA2 mRNA |
CTD |
PMID:12414654 PMID:12419474 PMID:15336504 PMID:23410634 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnb2 |
cyclin B2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CCNB2 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 8:76,847,972...76,861,165
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CCNE1 protein] |
CTD |
PMID:15606011 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Ccne2 |
cyclin E2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CCNE2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:24,434,077...24,446,406
Ensembl chr 5:24,434,872...24,446,406
|
|
G |
Ccnf |
cyclin F |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CCNF mRNA |
CTD |
PMID:15003993 |
|
NCBI chr10:13,594,687...13,619,935
Ensembl chr10:13,594,687...13,619,935
|
|
G |
Ccng2 |
cyclin G2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CCNG2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr14:16,267,572...16,276,068
Ensembl chr14:16,267,573...16,276,068
|
|
G |
Ccnj |
cyclin J |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CCNJ mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:259,926,537...259,944,275
Ensembl chr 1:260,093,641...260,111,254 Ensembl chr 1:260,093,641...260,111,254
|
|
G |
Ccnk |
cyclin K |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CCNK mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 6:132,090,235...132,113,560
Ensembl chr 6:132,090,218...132,113,557
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CCS mRNA |
CTD |
PMID:14729362 PMID:15336504 |
|
NCBI chr 1:220,075,251...220,096,319
Ensembl chr 1:220,075,247...220,096,404
|
|
G |
Cd24 |
CD24 molecule |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CD24 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:48,335,540...48,340,847
Ensembl chr20:48,335,540...48,340,846
|
|
G |
Cd320 |
CD320 molecule |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CD320 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:18,700,445...18,706,244
Ensembl chr 7:18,700,344...18,706,244
|
|
G |
Cd46 |
CD46 molecule |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CD46 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:113,786,525...113,818,741
Ensembl chr13:113,787,349...113,817,995
|
|
G |
Cd47 |
Cd47 molecule |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CD47 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr11:53,511,485...53,575,754
Ensembl chr11:53,514,595...53,575,175
|
|
G |
Cd55 |
CD55 molecule (Cromer blood group) |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CD55 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:47,125,156...47,153,557
Ensembl chr13:47,126,741...47,154,292
|
|
G |
Cd68 |
Cd68 molecule |
increases expression decreases response to substance |
ISO |
tert-Butylhydroperoxide results in increased expression of CD68 mRNA CD68 protein results in decreased susceptibility to tert-Butylhydroperoxide |
CTD |
PMID:14729362 PMID:15003993 PMID:15336504 |
|
NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
|
|
G |
Cd82 |
Cd82 molecule |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CD82 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:82,324,344...82,368,846
Ensembl chr 3:82,324,354...82,368,357
|
|
G |
Cd9 |
CD9 molecule |
decreases expression affects expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CD9 mRNA tert-Butylhydroperoxide affects the expression of CD9 mRNA |
CTD |
PMID:15336504 PMID:23410634 |
|
NCBI chr 4:157,977,163...158,010,091
Ensembl chr 4:157,977,162...158,010,166
|
|
G |
Cd99 |
CD99 molecule (Xg blood group) |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CD99 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:56,192,426...56,196,961
Ensembl chr20:56,192,390...56,197,025
|
|
G |
Cdc16 |
cell division cycle 16 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDC16 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:81,493,355...81,516,493
Ensembl chr16:81,493,355...81,516,493
|
|
G |
Cdc25b |
cell division cycle 25B |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDC25B mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:123,731,539...123,741,696
Ensembl chr 3:123,731,539...123,741,339
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression increases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDC25C mRNA tert-Butylhydroperoxide results in increased expression of CDC25C mRNA |
CTD |
PMID:12419474 PMID:14729362 PMID:15003993 |
|
NCBI chr18:27,528,768...27,550,316
Ensembl chr18:27,528,354...27,550,224
|
|
G |
Cdc27 |
cell division cycle 27 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CDC27 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:92,551,754...92,602,214
Ensembl chr10:92,554,081...92,602,082
|
|
G |
Cdc37l1 |
cell division cycle 37-like 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDC37L1 mRNA |
CTD |
PMID:15963989 |
|
NCBI chr 1:247,110,147...247,139,113
Ensembl chr 1:247,107,397...247,138,155
|
|
G |
Cdc42 |
cell division cycle 42 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CDC42 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:155,690,267...155,728,385
Ensembl chr 5:155,691,390...155,728,300
|
|
G |
Cdc42ep2 |
CDC42 effector protein 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CDC42EP2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:221,272,349...221,281,252
Ensembl chr 1:221,272,353...221,281,180
|
|
G |
Cdc42ep3 |
CDC42 effector protein 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CDC42EP3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:1,922,500...1,942,972
Ensembl chr 6:1,922,500...1,942,972
|
|
G |
Cdc42ep4 |
CDC42 effector protein 4 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of CDC42EP4 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr10:102,244,680...102,269,272
Ensembl chr10:102,244,681...102,269,272
|
|
G |
Cdc42se1 |
CDC42 small effector 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CDC42SE1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:196,402,837...196,410,664
Ensembl chr 2:196,402,837...196,410,659
|
|
G |
Cdc5l |
cell division cycle 5-like |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDC5L mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:17,949,764...17,988,514
Ensembl chr 9:17,949,764...17,988,509
|
|
G |
Cdca3 |
cell division cycle associated 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDCA3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:157,347,876...157,351,889
Ensembl chr 4:157,348,020...157,351,604
|
|
G |
Cdcp1 |
CUB domain containing protein 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CDCP1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:132,260,007...132,296,661
Ensembl chr 8:132,260,029...132,296,661
|
|
G |
Cdh11 |
cadherin 11 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDH11 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr19:2,391,181...2,551,245
Ensembl chr19:2,393,059...2,551,245
|
|
G |
Cdh3 |
cadherin 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDH3 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr19:38,668,957...38,719,801
Ensembl chr19:38,669,230...38,719,677
|
|
G |
Cdh5 |
cadherin 5 |
increases expression |
EXP |
tert-Butylhydroperoxide results in increased expression of CDH5 mRNA |
CTD |
PMID:22659508 |
|
NCBI chr19:1,025,122...1,074,333
Ensembl chr19:1,023,683...1,074,365
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CDK1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdk10 |
cyclin-dependent kinase 10 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDK10 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr19:56,024,903...56,032,610
Ensembl chr19:56,024,903...56,032,605
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases activity decreases expression multiple interactions |
ISO |
tert-Butylhydroperoxide results in decreased activity of CDK2 protein tert-Butylhydroperoxide results in decreased expression of CDK2 mRNA ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDK2 protein] |
CTD |
PMID:12766906 PMID:15336504 PMID:15606011 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
tert-Butylhydroperoxide results in increased expression of CDKN1A mRNA; tert-Butylhydroperoxide results in increased expression of CDKN1A protein ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDKN1A protein]; Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1A protein]; Plant Extracts inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1A protein] |
CTD |
PMID:12414654 PMID:12766906 PMID:12782109 PMID:15336504 PMID:15606011 PMID:18619952 PMID:22563892 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
multiple interactions increases expression decreases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1C mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1C mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1C mRNA; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1C mRNA]; tert-Butylhydroperoxide promotes the reaction [PPARG protein binds to CDKN1C promoter]; troglitazone inhibits the reaction [tert-Butylhydroperoxide promotes the reaction [PPARG protein binds to CDKN1C promoter]]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1C mRNA] tert-Butylhydroperoxide results in decreased expression of CDKN1C mRNA |
CTD |
PMID:12419474 PMID:20847119 |
|
NCBI chr 1:216,661,067...216,663,791
Ensembl chr 1:216,661,080...216,663,721
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDKN2B mRNA |
CTD |
PMID:12419474 PMID:14729362 |
|
NCBI chr 5:107,834,353...107,857,428
Ensembl chr 5:107,845,951...107,858,104
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CDKN2C mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:129,347,731...129,352,886
Ensembl chr 5:129,347,732...129,352,886
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CDKN3 mRNA |
CTD |
PMID:15003993 PMID:27509014 |
|
NCBI chr15:23,553,171...23,564,538
Ensembl chr15:23,553,128...23,564,535
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of CEBPA mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CEBPB mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Celf2 |
CUGBP, Elav-like family member 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CELF2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr17:75,259,269...75,660,154
Ensembl chr17:75,352,389...75,654,951
|
|
G |
Celsr2 |
cadherin, EGF LAG seven-pass G-type receptor 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CELSR2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:211,183,410...211,207,458
Ensembl chr 2:211,183,311...211,207,465
|
|
G |
Cenpa |
centromere protein A |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CENPA mRNA |
CTD |
PMID:12414654 |
|
NCBI chr 6:27,072,259...27,080,863
Ensembl chr 6:27,072,166...27,080,856
|
|
G |
Cenpm |
centromere protein M |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CENPM mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:123,464,615...123,476,336
Ensembl chr 7:123,464,490...123,476,238
|
|
G |
Cep170 |
centrosomal protein 170 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CEP170 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:94,807,090...94,887,448
Ensembl chr13:94,807,756...94,859,436
|
|
G |
Cep170b |
centrosomal protein 170B |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CEP170B mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:137,283,814...137,311,512
Ensembl chr 6:137,288,810...137,311,932
|
|
G |
Cep192 |
centrosomal protein 192 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CEP192 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr18:63,572,084...63,656,302
Ensembl chr18:63,524,452...63,656,286
|
|
G |
Cep43 |
centrosomal protein 43 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CEP43 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:53,122,330...53,152,872
Ensembl chr 1:53,122,322...53,152,866
|
|
G |
Cep57 |
centrosomal protein 57 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CEP57 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:12,335,430...12,355,425
Ensembl chr 8:12,335,432...12,355,091
|
|
G |
Cep89 |
centrosomal protein 89 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CEP89 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:91,663,723...91,705,979
Ensembl chr 1:91,663,736...91,706,094
|
|
G |
Cfb |
complement factor B |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CFB mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:4,536,206...4,542,073
Ensembl chr20:4,536,203...4,561,066 Ensembl chr20:4,536,203...4,561,066
|
|
G |
Cfi |
complement factor I |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CFI mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:235,264,149...235,305,779
Ensembl chr 2:235,264,219...235,305,781
|
|
G |
Chaf1a |
chromatin assembly factor 1 subunit A |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CHAF1A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:11,000,869...11,027,631
Ensembl chr 9:11,001,129...11,027,506
|
|
G |
Chdh |
choline dehydrogenase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CHDH mRNA |
CTD |
PMID:27509014 |
|
NCBI chr16:6,078,083...6,109,386
Ensembl chr16:6,078,122...6,109,382
|
|
G |
Chek1 |
checkpoint kinase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CHEK1 mRNA |
CTD |
PMID:12414654 |
|
NCBI chr 8:39,181,162...39,201,588
Ensembl chr 8:39,181,163...39,243,882
|
|
G |
Chka |
choline kinase alpha |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of CHKA mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 1:219,076,618...219,126,221
Ensembl chr 1:219,077,771...219,126,220
|
|
G |
Chmp2a |
charged multivesicular body protein 2A |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CHMP2A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:65,540,808...65,543,708
Ensembl chr 1:65,541,322...65,543,707
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CHORDC1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:17,421,552...17,445,513
Ensembl chr 8:17,421,557...17,446,165
|
|
G |
Chrdl1 |
chordin-like 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CHRDL1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr X:114,554,359...114,658,975
Ensembl chr X:114,554,359...114,658,931
|
|
G |
Chst15 |
carbohydrate sulfotransferase 15 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of CHST15 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 1:204,243,396...204,328,960
Ensembl chr 1:204,245,645...204,322,544
|
|
G |
Chst2 |
carbohydrate sulfotransferase 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CHST2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:103,186,759...103,190,612
Ensembl chr 8:103,188,651...103,190,243
|
|
G |
Clasp1 |
cytoplasmic linker associated protein 1 |
decreases methylation decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased methylation of CLASP1 intron tert-Butylhydroperoxide results in decreased expression of CLASP1 mRNA |
CTD |
PMID:29432895 |
|
NCBI chr13:34,365,038...34,584,651
Ensembl chr13:34,365,147...34,584,651
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CLCN3 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr16:32,448,821...32,520,649
Ensembl chr16:32,449,116...32,519,148
|
|
G |
Clic3 |
chloride intracellular channel 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CLIC3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:2,675,732...2,678,248
Ensembl chr 3:2,676,296...2,680,565
|
|
G |
Cln3 |
CLN3 lysosomal/endosomal transmembrane protein, battenin |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CLN3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:197,986,384...197,999,726
Ensembl chr 1:197,986,385...197,997,664
|
|
G |
Cln6 |
CLN6, transmembrane ER protein |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CLN6 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 8:67,733,215...67,748,170
Ensembl chr 8:67,733,215...67,748,172
|
|
G |
Clstn1 |
calsyntenin 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CLSTN1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:166,533,262...166,601,686
Ensembl chr 5:166,533,181...166,601,684
|
|
G |
Clu |
clusterin |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CLU mRNA |
CTD |
PMID:15963989 |
|
NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
|
|
G |
Cmtm1 |
CKLF-like MARVEL transmembrane domain containing 1 |
decreases methylation |
ISO |
tert-Butylhydroperoxide results in decreased methylation of CMTM1 gene |
CTD |
PMID:29432895 |
|
NCBI chr19:849,145...869,508
Ensembl chr19:859,948...869,490
|
|
G |
Cndp2 |
carnosine dipeptidase 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CNDP2 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr18:81,521,966...81,539,065
Ensembl chr18:81,521,968...81,539,065
|
|
G |
Cnnm3 |
cyclin and CBS domain divalent metal cation transport mediator 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CNNM3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:43,093,120...43,108,486
Ensembl chr 9:43,093,138...43,108,486
|
|
G |
Cnot8 |
CCR4-NOT transcription complex, subunit 8 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CNOT8 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:43,538,150...43,551,271
Ensembl chr10:43,538,160...43,551,271
|
|
G |
Cog5 |
component of oligomeric golgi complex 5 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COG5 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:50,953,868...51,230,860
Ensembl chr 6:50,954,631...51,230,701
|
|
G |
Cog8 |
component of oligomeric golgi complex 8 |
multiple interactions decreases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of COG8 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of COG8 mRNA; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of COG8 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr19:39,246,656...39,257,406
Ensembl chr19:39,246,625...39,257,451
|
|
G |
Col13a1 |
collagen type XIII alpha 1 chain |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of COL13A1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:31,456,502...31,598,360
Ensembl chr20:31,456,852...31,598,118
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COL1A2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COL3A1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COL4A1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:83,522,162...83,632,153
Ensembl chr16:83,522,162...83,632,153
|
|
G |
Col4a2 |
collagen type IV alpha 2 chain |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COL4A2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:83,386,388...83,522,169
Ensembl chr16:83,387,364...83,438,561
|
|
G |
Col5a1 |
collagen type V alpha 1 chain |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COL5A1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:6,430,180...6,581,010
Ensembl chr 3:6,430,201...6,578,882
|
|
G |
Col5a2 |
collagen type V alpha 2 chain |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COL5A2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:52,091,088...52,238,735
Ensembl chr 9:52,092,511...52,238,564
|
|
G |
Col6a1 |
collagen type VI alpha 1 chain |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of COL6A1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:12,657,913...12,676,370
Ensembl chr20:12,658,065...12,675,561
|
|
G |
Col6a2 |
collagen type VI alpha 2 chain |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of COL6A2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:12,773,472...12,801,179
Ensembl chr20:12,773,427...12,801,180
|
|
G |
Col7a1 |
collagen type VII alpha 1 chain |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of COL7A1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:117,694,441...117,726,844
Ensembl chr 8:117,694,605...117,726,844
|
|
G |
Col8a2 |
collagen type VIII alpha 2 chain |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COL8A2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:144,308,527...144,335,142
Ensembl chr 5:144,308,611...144,335,172
|
|
G |
Comt |
catechol-O-methyltransferase |
decreases expression |
ISO EXP |
tert-Butylhydroperoxide results in decreased expression of COMT mRNA tert-Butylhydroperoxide results in decreased expression of COMT protein |
CTD |
PMID:12419474 PMID:24394546 |
|
NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
|
|
G |
Copa |
COPI coat complex subunit alpha |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COPA mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:90,467,285...90,508,894
Ensembl chr13:90,467,265...90,508,932
|
|
G |
Copb1 |
COPI coat complex subunit beta 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of COPB1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:183,695,480...183,729,569
Ensembl chr 1:183,695,481...183,729,569
|
|
G |
Cope |
COPI coat complex subunit epsilon |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COPE mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:20,863,141...20,873,516
Ensembl chr16:20,863,141...20,873,521
|
|
G |
Cops6 |
COP9 signalosome subunit 6 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COPS6 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:19,303,387...19,306,226
Ensembl chr12:19,303,387...19,306,226
|
|
G |
Cops8 |
COP9 signalosome subunit 8 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of COPS8 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:97,772,224...97,782,055
Ensembl chr 9:97,772,184...97,782,067
|
|
G |
Cox7a1 |
cytochrome c oxidase subunit 7A1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of COX7A1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:88,619,619...88,650,672
Ensembl chr 1:91,071,493...91,074,294 Ensembl chr 1:91,071,493...91,074,294
|
|
G |
Cp |
ceruloplasmin |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CP mRNA |
CTD |
PMID:14729362 |
|
NCBI chr 2:104,744,249...104,803,034
Ensembl chr 2:104,744,461...104,799,853
|
|
G |
Cpe |
carboxypeptidase E |
decreases expression increases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CPE mRNA tert-Butylhydroperoxide results in increased expression of CPE mRNA |
CTD |
PMID:12419474 PMID:15336504 |
|
NCBI chr16:26,906,716...27,014,811
Ensembl chr16:26,906,716...27,014,813
|
|
G |
Cpm |
carboxypeptidase M |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CPM mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:60,654,350...60,714,620
Ensembl chr 7:60,654,350...60,714,620
|
|
G |
Cpne1 |
copine 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CPNE1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:151,617,733...151,625,448 NCBI chr 3:152,150,143...152,192,936
Ensembl chr 3:151,616,037...151,625,644 Ensembl chr 3:151,616,037...151,625,644
|
|
G |
Cpq |
carboxypeptidase Q |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CPQ mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:71,709,174...72,167,413
Ensembl chr 7:71,709,157...72,167,417
|
|
G |
Crat |
carnitine O-acetyltransferase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CRAT mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:8,967,984...8,981,959
Ensembl chr 3:8,968,417...8,981,362
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
decreases expression increases phosphorylation multiple interactions |
ISO |
tert-Butylhydroperoxide results in decreased expression of CREB1 mRNA tert-Butylhydroperoxide results in increased phosphorylation of CREB1 protein U 0126 inhibits the reaction [tert-Butylhydroperoxide results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:12419474 PMID:17003459 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crip1 |
cysteine rich protein 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CRIP1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 6:137,959,171...137,967,042
Ensembl chr 6:137,959,171...137,967,042
|
|
G |
Crispld2 |
cysteine-rich secretory protein LCCL domain containing 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CRISPLD2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:52,647,038...52,705,118
Ensembl chr19:52,647,070...52,705,131
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions decreases expression increases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CRYAB mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CRYAB mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CRYAB mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CRYAB mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CRYAB mRNA] tert-Butylhydroperoxide results in decreased expression of CRYAB mRNA |
CTD |
PMID:15336504 PMID:20847119 |
|
NCBI chr 8:55,178,543...55,182,546
Ensembl chr 8:55,178,289...55,182,545
|
|
G |
Cryz |
crystallin zeta |
decreases response to substance increases expression |
ISO |
CRYZ protein results in decreased susceptibility to tert-Butylhydroperoxide tert-Butylhydroperoxide results in increased expression of CRYZ mRNA |
CTD |
PMID:14729362 PMID:15003993 PMID:15336504 |
|
NCBI chr 2:260,884,315...260,911,827
Ensembl chr 2:260,884,337...260,911,792
|
|
G |
Csf1 |
colony stimulating factor 1 |
decreases response to substance |
ISO |
CSF1 protein results in decreased susceptibility to tert-Butylhydroperoxide |
CTD |
PMID:16446085 |
|
NCBI chr 2:210,522,370...210,550,546
Ensembl chr 2:210,522,375...210,550,560
|
|
G |
Csnk1d |
casein kinase 1, delta |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CSNK1D mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:110,147,786...110,182,413
Ensembl chr10:110,148,600...110,182,408
|
|
G |
Cspg4 |
chondroitin sulfate proteoglycan 4 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CSPG4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:61,532,465...61,567,510
Ensembl chr 8:61,532,465...61,567,510
|
|
G |
Ctdspl |
CTD small phosphatase like |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CTDSPL mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:127,065,292...127,726,248
Ensembl chr 8:127,702,534...127,726,127
|
|
G |
Cth |
cystathionine gamma-lyase |
increases activity |
EXP |
tert-Butylhydroperoxide results in increased activity of CTH protein |
CTD |
PMID:18184479 |
|
NCBI chr 2:264,266,959...264,293,040
Ensembl chr 2:264,266,984...264,293,046
|
|
G |
Ctnna1 |
catenin alpha 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CTNNA1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr18:27,923,229...28,055,972
Ensembl chr18:27,923,572...28,055,960
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CTNNB1 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CTNNB1 mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CTNNB1 mRNA; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CTNNB1 mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CTNNB1 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Ctsb |
cathepsin B |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CTSB mRNA |
CTD |
PMID:15336504 |
|
NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
|
|
G |
Ctsl |
cathepsin L |
increases expression decreases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CTSL mRNA tert-Butylhydroperoxide results in decreased expression of CTSL mRNA |
CTD |
PMID:12419474 PMID:15336504 |
|
NCBI chr17:1,873,105...1,879,266
Ensembl chr17:1,872,848...1,879,279
|
|
G |
Cttn |
cortactin |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CTTN mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 1:217,602,698...217,638,196 NCBI chr 1:215,255,385...215,290,882
Ensembl chr 1:217,602,698...217,638,152 Ensembl chr 1:217,602,698...217,638,152
|
|
G |
Cul4a |
cullin 4A |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CUL4A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:81,718,784...81,756,653
Ensembl chr16:81,719,028...81,756,654
|
|
G |
Cux1 |
cut-like homeobox 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CUX1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr12:23,150,886...23,470,095
Ensembl chr12:23,151,180...23,445,074
|
|
G |
Cxadr |
CXADR, Ig-like cell adhesion molecule |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CXADR mRNA |
CTD |
PMID:15336504 |
|
NCBI chr11:16,826,269...16,873,564
Ensembl chr11:16,826,399...16,873,562
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CXCL1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CXCL10 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CXCL2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CXCL1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions increases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CXCR4 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CXCR4 mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CXCR4 mRNA; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CXCR4 mRNA]; tert-Butylhydroperoxide promotes the reaction [PPARG protein binds to CXCR4 promoter]; troglitazone inhibits the reaction [tert-Butylhydroperoxide promotes the reaction [PPARG protein binds to CXCR4 promoter]]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CXCR4 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
|
|
G |
Cxxc5 |
CXXC finger protein 5 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CXXC5 mRNA |
CTD |
PMID:29432895 |
|
NCBI chr18:28,626,386...28,656,916
Ensembl chr18:28,653,592...28,656,937
|
|
G |
Cyb561 |
cytochrome b-561 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CYB561 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:94,136,993...94,147,567
Ensembl chr10:94,136,993...94,147,621
|
|
G |
Cyb5d2 |
cytochrome b5 domain containing 2 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of CYB5D2 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr10:59,343,347...59,360,979
Ensembl chr10:59,344,470...59,360,661
|
|
G |
Cyb5r2 |
cytochrome b5 reductase 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CYB5R2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:171,971,424...171,981,586
Ensembl chr 1:171,971,701...171,979,933
|
|
G |
Cybc1 |
cytochrome b-245 chaperone 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of CYBC1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:110,424,973...110,431,792
Ensembl chr10:110,424,974...110,431,792
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization multiple interactions |
ISO |
tert-Butylhydroperoxide affects the localization of CYCS protein hyperoside inhibits the reaction [tert-Butylhydroperoxide affects the localization of CYCS protein] |
CTD |
PMID:18552516 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Cygb |
cytoglobin |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CYGB mRNA |
CTD |
PMID:27509014 |
|
NCBI chr10:105,618,325...105,628,091
Ensembl chr10:105,618,326...105,628,091
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CYP1B1 mRNA |
CTD |
PMID:12414654 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of CYP24A1 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 3:168,097,484...168,111,920
Ensembl chr 3:168,097,485...168,111,920
|
|
G |
Cyria |
CYFIP related Rac1 interactor A |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of CYRIA mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:37,555,167...37,661,196
Ensembl chr 6:37,555,182...37,665,064
|
|
G |
Dap3 |
death associated protein 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DAP3 mRNA |
CTD |
PMID:14729362 |
|
NCBI chr 2:188,225,607...188,255,324
Ensembl chr 2:188,225,613...188,252,725
|
|
G |
Dapk1 |
death associated protein kinase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DAPK1 mRNA |
CTD |
PMID:12419474 PMID:15336504 |
|
NCBI chr17:4,297,038...4,454,941
Ensembl chr17:4,297,224...4,454,778
|
|
G |
Dars1 |
aspartyl-tRNA synthetase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DARS1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:45,074,067...45,127,815
Ensembl chr13:45,074,072...45,127,815
|
|
G |
Dazap2 |
DAZ associated protein 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DAZAP2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:142,238,780...142,244,301
Ensembl chr 7:142,239,035...142,243,241
|
|
G |
Dbi |
diazepam binding inhibitor, acyl-CoA binding protein |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DBI mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:36,147,667...36,156,076
Ensembl chr13:36,117,119...36,174,908
|
|
G |
Dcaf7 |
DDB1 and CUL4 associated factor 7 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DCAF7 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:94,231,585...94,254,046
Ensembl chr10:94,231,585...94,254,046
|
|
G |
Dctn5 |
dynactin subunit 5 |
decreases methylation |
ISO |
tert-Butylhydroperoxide results in decreased methylation of DCTN5 gene |
CTD |
PMID:29432895 |
|
NCBI chr 1:192,088,709...192,105,421
Ensembl chr 1:192,088,672...192,105,429
|
|
G |
Ddb2 |
damage specific DNA binding protein 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DDB2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:80,030,437...80,052,984
Ensembl chr 3:80,030,437...80,052,953
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO EXP |
tert-Butylhydroperoxide results in increased expression of DDIT3 mRNA; tert-Butylhydroperoxide results in increased expression of DDIT3 protein Acetylcysteine inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DDIT3 protein]; ETFA mutant form inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DDIT3 protein] |
CTD |
PMID:12414654 PMID:22659508 PMID:24394546 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of DDIT4 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DDR1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:3,553,430...3,574,959
Ensembl chr20:3,552,929...3,575,780
|
|
G |
Ddx11 |
DEAD/H-box helicase 11 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DDX11 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:114,113,642...114,133,908
Ensembl chr 9:114,111,580...114,132,492
|
|
G |
Ddx21 |
DExD-box helicase 21 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DDX21 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:32,213,147...32,232,632
Ensembl chr20:32,213,148...32,232,632
|
|
G |
Ddx42 |
DEAD-box helicase 42 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DDX42 mRNA |
CTD |
PMID:12414654 |
|
NCBI chr10:94,407,094...94,439,052
Ensembl chr10:94,407,559...94,439,052
|
|
G |
Ddx43 |
DEAD-box helicase 43 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DDX43 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:85,749,499...85,779,068
Ensembl chr 8:85,750,082...85,777,510
|
|
G |
Ddx50 |
DExD-box helicase 50 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DDX50 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr20:32,239,736...32,269,522
Ensembl chr20:32,239,748...32,269,145
|
|
G |
Ddx52 |
DExD-box helicase 52 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DDX52 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:71,253,667...71,276,397
Ensembl chr10:71,253,598...71,277,277
|
|
G |
Ddx56 |
DEAD-box helicase 56 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DDX56 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr14:86,378,937...86,387,637
Ensembl chr14:86,376,808...86,387,608
|
|
G |
Ddx6 |
DEAD-box helicase 6 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DDX6 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 8:48,924,768...48,961,394
Ensembl chr 8:48,925,604...48,958,026
|
|
G |
Dennd3 |
DENN domain containing 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DENND3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:114,724,644...114,812,471
Ensembl chr 7:114,724,610...114,812,708
|
|
G |
Depp1 |
DEPP1, autophagy regulator |
multiple interactions increases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of DEPP1 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of DEPP1 mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of DEPP1 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DEPP1 mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DEPP1 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 4:148,780,330...148,784,566
Ensembl chr 4:148,782,479...148,784,562
|
|
G |
Derl1 |
derlin 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DERL1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 7:97,737,176...97,759,852
Ensembl chr 7:97,737,178...97,759,852
|
|
G |
Dffb |
DNA fragmentation factor subunit beta |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DFFB mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 5:171,250,559...171,261,875
Ensembl chr 5:171,249,633...171,262,119
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of DGAT2 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 1:164,113,459...164,143,818
Ensembl chr 1:164,113,459...164,143,818
|
|
G |
Dhps |
deoxyhypusine synthase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DHPS mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:26,184,665...26,188,755
Ensembl chr19:26,184,545...26,188,832
|
|
G |
Dhx9 |
DExH-box helicase 9 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DHX9 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:70,885,503...70,922,278
Ensembl chr13:70,885,504...70,922,245
|
|
G |
Dimt1 |
DIMT1 rRNA methyltransferase and ribosome maturation factor |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DIMT1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:38,120,562...38,144,871
Ensembl chr 2:38,120,592...38,144,327
|
|
G |
Dip2c |
disco-interacting protein 2 homolog C |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DIP2C mRNA |
CTD |
PMID:15336504 |
|
NCBI chr17:63,426,688...63,810,183
Ensembl chr17:63,635,086...63,808,464
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DKK1 mRNA |
CTD |
PMID:12414654 PMID:15336504 |
|
NCBI chr 1:248,952,896...248,956,579
Ensembl chr 1:248,895,738...248,898,607
|
|
G |
Dlg1 |
discs large MAGUK scaffold protein 1 |
multiple interactions increases expression |
ISO |
[rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of DLG1 mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of DLG1 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DLG1 mRNA]; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DLG1 mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DLG1 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr11:72,164,566...72,378,895
Ensembl chr11:72,163,749...72,378,895
|
|
G |
Dlg3 |
discs large MAGUK scaffold protein 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DLG3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr X:70,596,246...70,648,529
Ensembl chr X:70,596,576...70,648,532
|
|
G |
Dlgap4 |
DLG associated protein 4 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DLGAP4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:152,752,091...152,846,118
Ensembl chr 3:152,752,091...152,846,118
|
|
G |
Dlgap5 |
DLG associated protein 5 |
increases expression affects expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DLGAP5 mRNA tert-Butylhydroperoxide affects the expression of DLGAP5 mRNA |
CTD |
PMID:15003993 PMID:23410634 |
|
NCBI chr15:24,167,484...24,199,417
Ensembl chr15:24,167,486...24,199,341
|
|
G |
Dlx2 |
distal-less homeobox 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DLX2 mRNA |
CTD |
PMID:14729362 PMID:29432895 |
|
NCBI chr 3:58,180,088...58,181,971
Ensembl chr 3:58,180,088...58,181,971
|
|
G |
Dmpk |
DM1 protein kinase |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DMPK mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:79,988,096...79,999,358
Ensembl chr 1:79,989,019...79,999,364
|
|
G |
Dnaaf2 |
dynein, axonemal, assembly factor 2 |
multiple interactions decreases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of DNAAF2 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of DNAAF2 mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of DNAAF2 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of DNAAF2 mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of DNAAF2 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 6:91,481,439...91,490,189
Ensembl chr 6:91,481,954...91,490,366
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DNAJB1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DNAJB11 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr11:81,741,342...81,757,806
Ensembl chr11:81,741,297...81,757,813
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DNAJB4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:257,394,692...257,425,344
Ensembl chr 2:257,394,818...257,425,242
|
|
G |
Dnajb7 |
DnaJ heat shock protein family (Hsp40) member B7 |
decreases methylation |
ISO |
tert-Butylhydroperoxide results in decreased methylation of DNAJB7 intron |
CTD |
PMID:29432895 |
|
NCBI chr 7:122,642,740...122,644,054
Ensembl chr 7:122,642,740...122,644,054
|
|
G |
Dnase2 |
deoxyribonuclease 2, lysosomal |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DNASE2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:26,022,855...26,025,523
Ensembl chr19:26,022,849...26,025,532
|
|
G |
Dnm2 |
dynamin 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DNM2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:22,458,869...22,540,649
Ensembl chr 8:22,458,899...22,540,524
|
|
G |
Dnmbp |
dynamin binding protein |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DNMBP mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:263,625,503...263,718,784
Ensembl chr 1:263,625,501...263,718,745
|
|
G |
Dnph1 |
2'-deoxynucleoside 5'-phosphate N-hydrolase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DNPH1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 9:16,845,764...16,848,514
Ensembl chr 9:16,845,525...16,848,503
|
|
G |
Dock2 |
dedicator of cytokinesis 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DOCK2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:19,181,512...19,603,171
|
|
G |
Dock4 |
dedicator of cytokinesis 4 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DOCK4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:60,374,839...60,782,648
Ensembl chr 6:60,566,196...60,782,556
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DPP4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:48,291,055...48,372,672
Ensembl chr 3:48,291,055...48,372,672
|
|
G |
Dpy19l1 |
dpy-19 like C-mannosyltransferase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DPY19L1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:25,582,938...25,669,394
Ensembl chr 8:25,582,938...25,669,394
|
|
G |
Dpysl3 |
dihydropyrimidinase-like 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DPYSL3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr18:37,716,371...37,819,347
Ensembl chr18:37,716,143...37,819,097
|
|
G |
Drap1 |
Dr1 associated protein 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DRAP1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:220,803,783...220,806,480
Ensembl chr 1:220,803,796...220,806,433
|
|
G |
Dsc3 |
desmocollin 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DSC3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr18:11,753,047...11,789,846
Ensembl chr18:11,753,047...11,789,708
|
|
G |
Dst |
dystonin |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DST mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 9:37,902,336...38,296,961
Ensembl chr 9:37,902,303...38,196,273
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of DUSP1 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
multiple interactions increases expression |
ISO |
[Pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of DUSP10 mRNA; [Rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of DUSP10 mRNA; [Troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of DUSP10 mRNA; Rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DUSP10 mRNA]; Troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DUSP10 mRNA] |
CTD |
PMID:15336504 PMID:20847119 |
|
NCBI chr13:104,284,660...104,321,455
Ensembl chr13:104,284,660...104,321,455
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of DUSP5 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:274,245,184...274,258,595
Ensembl chr 1:274,245,184...274,258,595
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
decreases expression increases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DUSP6 mRNA tert-Butylhydroperoxide results in increased expression of DUSP6 mRNA |
CTD |
PMID:15336504 PMID:17003459 |
|
NCBI chr 7:41,475,163...41,479,393
Ensembl chr 7:41,475,163...41,479,392
|
|
G |
Dusp9 |
dual specificity phosphatase 9 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of DUSP9 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr X:157,168,143...157,172,068
Ensembl chr X:157,168,144...157,172,068
|
|
G |
Dut |
deoxyuridine triphosphatase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DUT mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:117,514,399...117,525,450
Ensembl chr 3:117,514,444...117,525,446
|
|
G |
Dvl3 |
dishevelled segment polarity protein 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DVL3 mRNA |
CTD |
PMID:29432895 |
|
NCBI chr11:84,051,177...84,068,479
Ensembl chr11:84,051,078...84,068,302
|
|
G |
Dynll1 |
dynein light chain LC8-type 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DYNLL1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr12:47,074,200...47,076,573
Ensembl chr12:47,074,200...47,076,572
|
|
G |
Dynlrb1 |
dynein light chain roadblock-type 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of DYNLRB1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:150,761,329...150,782,493
Ensembl chr 3:150,761,329...150,782,493
|
|
G |
E2f1 |
E2F transcription factor 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of E2F1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
Ech1 |
enoyl-CoA hydratase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ECH1 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:87,009,798...87,015,996
Ensembl chr 1:87,009,730...87,016,005
|
|
G |
Echdc2 |
enoyl CoA hydratase domain containing 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ECHDC2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:127,770,570...127,789,568
Ensembl chr 5:127,770,570...127,789,567
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
decreases expression |
EXP |
tert-Butylhydroperoxide results in decreased expression of ECHS1 protein |
CTD |
PMID:24394546 |
|
NCBI chr 1:212,570,213...212,579,040
Ensembl chr 1:212,570,195...212,579,057
|
|
G |
Eci1 |
enoyl-CoA delta isomerase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ECI1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:13,797,573...13,810,918
Ensembl chr10:13,797,562...13,810,913
|
|
G |
Ecsit |
ECSIT signaling integrator |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ECSIT mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:23,085,598...23,099,064
Ensembl chr 8:23,085,590...23,099,042
|
|
G |
Edil3 |
EGF like repeats and discoidin domains 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EDIL3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:17,616,116...18,128,514
Ensembl chr 2:17,616,401...18,128,512
|
|
G |
Edn1 |
endothelin 1 |
increases expression affects expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EDN1 mRNA tert-Butylhydroperoxide affects the expression of EDN1 mRNA |
CTD |
PMID:12414654 PMID:23410634 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
decreases expression |
EXP |
tert-Butylhydroperoxide results in decreased expression of EEF2 protein |
CTD |
PMID:16469450 |
|
NCBI chr 7:11,401,501...11,406,771
Ensembl chr 7:11,401,501...11,406,771
|
|
G |
Efemp1 |
EGF containing fibulin extracellular matrix protein 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EFEMP1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr14:113,202,382...113,294,993
Ensembl chr14:113,202,419...113,295,014
|
|
G |
Efhd1 |
EF-hand domain family, member D1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EFHD1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:94,362,249...94,408,884
Ensembl chr 9:94,362,299...94,408,885
|
|
G |
Efna4 |
ephrin A4 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EFNA4 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 2:188,655,920...188,660,179
Ensembl chr 2:188,655,912...188,660,179
|
|
G |
Efs |
embryonal Fyn-associated substrate |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EFS mRNA |
CTD |
PMID:15336504 |
|
NCBI chr15:33,579,952...33,590,217
Ensembl chr15:33,578,381...33,589,522
|
|
G |
Egr1 |
early growth response 1 |
increases expression affects expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EGR1 mRNA tert-Butylhydroperoxide affects the expression of EGR1 mRNA |
CTD |
PMID:12414654 PMID:23410634 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Eif2ak2 |
eukaryotic translation initiation factor 2-alpha kinase 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EIF2AK2 mRNA |
CTD |
PMID:14729362 PMID:15003993 |
|
NCBI chr 6:1,428,845...1,466,193
Ensembl chr 6:1,428,834...1,466,201
|
|
G |
Eif2b4 |
eukaryotic translation initiation factor 2B subunit delta |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EIF2B4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:26,546,917...26,552,474
Ensembl chr 6:26,546,924...26,552,430
|
|
G |
Eif3m |
eukaryotic translation initiation factor 3, subunit M |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EIF3M mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:94,990,086...95,007,690
Ensembl chr 3:94,990,068...95,007,712
|
|
G |
Eif5 |
eukaryotic translation initiation factor 5 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EIF5 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:136,002,983...136,011,409
Ensembl chr 6:136,004,214...136,011,406
|
|
G |
Eif5b |
eukaryotic translation initiation factor 5B |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EIF5B mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:44,658,724...44,713,518
Ensembl chr 9:44,681,494...44,713,199
|
|
G |
Elavl1 |
ELAV like RNA binding protein 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ELAVL1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:2,461,502...2,502,432
Ensembl chr12:2,461,502...2,502,432
|
|
G |
Elf1 |
E74 like ETS transcription factor 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ELF1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr15:61,772,544...61,868,442
Ensembl chr15:61,826,711...61,868,343
|
|
G |
Elf5 |
E74 like ETS transcription factor 5 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ELF5 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 3:93,333,514...93,374,454
Ensembl chr 3:93,351,619...93,371,656
|
|
G |
Elob |
elongin B |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ELOB mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:13,163,032...13,168,217
Ensembl chr10:13,163,036...13,168,217
|
|
G |
Eme1 |
essential meiotic structure-specific endonuclease 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EME1 mRNA |
CTD |
PMID:27509014 |
|
NCBI chr10:82,366,820...82,375,510
Ensembl chr10:82,367,084...82,374,171
|
|
G |
Emilin1 |
elastin microfibril interfacer 1 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of EMILIN1 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 6:26,821,249...26,829,013
Ensembl chr 6:26,821,255...26,828,972
|
|
G |
Eml1 |
EMAP like 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EML1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:132,367,342...132,450,488
Ensembl chr 6:132,383,337...132,450,393
|
|
G |
Eml4 |
EMAP like 4 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EML4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 6:6,618,370...6,674,550
Ensembl chr 6:6,619,076...6,674,554
|
|
G |
Emp3 |
epithelial membrane protein 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EMP3 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 1:101,900,731...101,903,948
Ensembl chr 1:101,900,733...101,903,910
|
|
G |
Eng |
endoglin |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ENG mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:11,679,530...11,717,486
Ensembl chr 3:11,679,530...11,717,485
|
|
G |
Epb41l2 |
erythrocyte membrane protein band 4.1-like 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EPB41L2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:20,881,820...21,067,713
Ensembl chr 1:20,893,995...20,962,526
|
|
G |
Epb42 |
erythrocyte membrane protein band 4.2 |
increases degradation |
ISO |
tert-Butylhydroperoxide results in increased degradation of EPB42 protein |
CTD |
PMID:15040847 |
|
NCBI chr 3:112,967,095...112,985,318
Ensembl chr 3:112,965,653...112,985,318
|
|
G |
Ephb2 |
Eph receptor B2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EPHB2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 5:155,024,478...155,143,539
Ensembl chr 5:155,022,493...155,204,456
|
|
G |
Ephb4 |
EPH receptor B4 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EPHB4 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:22,393,338...22,418,332
Ensembl chr12:22,393,330...22,417,980
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EPHX1 mRNA |
CTD |
PMID:21382384 |
|
NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of EPHX2 mRNA |
CTD |
PMID:14729362 |
|
NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ERBB2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ERBB4 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 9:75,021,790...76,178,936
Ensembl chr 9:75,021,790...75,528,644
|
|
G |
Erbin |
erbb2 interacting protein |
multiple interactions increases expression |
ISO |
[troglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of ERBIN mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ERBIN mRNA]; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ERBIN mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ERBIN mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 2:33,880,860...33,952,806
Ensembl chr 2:33,881,024...33,920,837
|
|
G |
Ercc5 |
ERCC excision repair 5, endonuclease |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ERCC5 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 9:50,928,847...50,970,962
Ensembl chr 9:50,925,619...50,970,955
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [tert-Butylhydroperoxide promotes the reaction [ERN1 protein binds to TRAF2 protein]]; ETFA mutant form inhibits the reaction [tert-Butylhydroperoxide promotes the reaction [ERN1 protein binds to TRAF2 protein]]; tert-Butylhydroperoxide promotes the reaction [ERN1 protein binds to TRAF2 protein] |
CTD |
PMID:24394546 |
|
NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ERP29 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:40,619,377...40,625,884
Ensembl chr12:40,619,377...40,625,883
|
|
G |
Esm1 |
endothelial cell-specific molecule 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ESM1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:45,104,392...45,113,130
Ensembl chr 2:45,104,305...45,113,131
|
|
G |
Ess2 |
ess-2 splicing factor homolog |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ESS2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr11:87,224,371...87,234,329
Ensembl chr11:87,224,421...87,233,326
|
|
G |
Etf1 |
eukaryotic translation termination factor 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ETF1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr18:27,698,693...27,725,694
Ensembl chr18:27,698,695...27,725,694
|
|
G |
Etfa |
electron transfer flavoprotein subunit alpha |
multiple interactions decreases expression increases expression |
ISO EXP |
ETFA mutant form inhibits the reaction [tert-Butylhydroperoxide promotes the reaction [ERN1 protein binds to TRAF2 protein]]; ETFA mutant form inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DDIT3 protein]; ETFA mutant form inhibits the reaction [tert-Butylhydroperoxide results in increased expression of NFKB1 protein]; pyrazolanthrone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ETFA protein] tert-Butylhydroperoxide results in decreased expression of ETFA protein |
CTD |
PMID:24394546 |
|
NCBI chr 8:60,028,786...60,086,352
Ensembl chr 8:60,028,789...60,086,403
|
|
G |
Etfb |
electron transfer flavoprotein subunit beta |
decreases expression increases methylation |
ISO |
tert-Butylhydroperoxide results in decreased expression of ETFB mRNA tert-Butylhydroperoxide results in increased methylation of ETFB gene |
CTD |
PMID:15336504 PMID:29432895 |
|
NCBI chr 1:98,472,776...98,486,940
Ensembl chr 1:98,472,745...98,486,976
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ETS1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 8:33,756,634...33,879,625
Ensembl chr 8:33,816,386...33,879,625
|
|
G |
Ets2 |
ETS proto-oncogene 2, transcription factor |
decreases expression increases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ETS2 mRNA tert-Butylhydroperoxide results in increased expression of ETS2 mRNA |
CTD |
PMID:12419474 PMID:15336504 |
|
NCBI chr11:36,075,709...36,092,495
Ensembl chr11:36,075,709...36,092,495
|
|
G |
Etv3 |
ETS variant transcription factor 3 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of ETV3 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 2:186,872,483...186,887,294
Ensembl chr 2:186,872,520...186,886,592
|
|
G |
Etv4 |
ETS variant transcription factor 4 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ETV4 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr10:89,685,058...89,700,300
Ensembl chr10:89,685,058...89,700,283
|
|
G |
Etv5 |
ETS variant transcription factor 5 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of ETV5 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr11:82,194,657...82,252,145
Ensembl chr11:82,194,657...82,252,139
|
|
G |
Exoc7 |
exocyst complex component 7 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EXOC7 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:105,242,152...105,259,795
Ensembl chr10:105,242,152...105,259,795
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EZH2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 4:77,284,404...77,347,011
Ensembl chr 4:77,284,404...77,347,011
|
|
G |
Ezr |
ezrin |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of EZR mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 1:47,287,872...47,331,412
Ensembl chr 1:47,287,874...47,331,412
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of F2RL1 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 2:25,222,324...25,235,275
Ensembl chr 2:25,222,328...25,235,275
|
|
G |
Fah |
fumarylacetoacetate hydrolase |
decreases expression |
EXP |
tert-Butylhydroperoxide results in decreased expression of FAH protein |
CTD |
PMID:24394546 |
|
NCBI chr 1:146,713,663...146,736,339
Ensembl chr 1:146,713,676...146,736,261
|
|
G |
Fam110b |
family with sequence similarity 110, member B |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FAM110B mRNA |
CTD |
PMID:29432895 |
|
NCBI chr 5:18,762,488...18,903,818
Ensembl chr 5:18,901,039...18,902,672
|
|
G |
Fam111a |
FAM111 trypsin like peptidase A |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FAM111A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:229,003,778...229,019,532
Ensembl chr 1:229,003,961...229,019,527
|
|
G |
Fam13b |
family with sequence similarity 13, member B |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FAM13B mRNA |
CTD |
PMID:15003993 |
|
NCBI chr18:27,223,345...27,304,462
Ensembl chr18:27,223,345...27,289,876
|
|
G |
Fam171a1 |
family with sequence similarity 171, member A1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FAM171A1 mRNA |
CTD |
PMID:29432895 |
|
NCBI chr17:79,030,150...79,149,480
Ensembl chr17:79,031,423...79,085,076
|
|
G |
Fam210a |
family with sequence similarity 210, member A |
multiple interactions increases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of FAM210A mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of FAM210A mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of FAM210A mRNA; rosiglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of FAM210A mRNA]; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of FAM210A mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr18:64,045,023...64,084,594
Ensembl chr18:64,045,432...64,084,556
|
|
G |
Fanci |
FA complementation group I |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FANCI mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:141,116,565...141,172,997
Ensembl chr 1:141,120,166...141,172,483
|
|
G |
Farp1 |
FERM, ARH/RhoGEF and pleckstrin domain protein 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FARP1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr15:106,375,298...106,625,837
Ensembl chr15:106,434,177...106,625,837
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FAS mRNA |
CTD |
PMID:12414654 PMID:27509014 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Fastk |
Fas-activated serine/threonine kinase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FASTK mRNA |
CTD |
PMID:12419474 PMID:15336504 |
|
NCBI chr 4:7,260,521...7,264,590
Ensembl chr 4:7,260,575...7,264,589
|
|
G |
Fbln1 |
fibulin 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FBLN1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:126,096,793...126,176,468
Ensembl chr 7:126,096,793...126,176,468
|
|
G |
Fbxo30 |
F-box protein 30 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FBXO30 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 1:5,366,119...5,389,774
Ensembl chr 1:5,366,379...5,388,069
|
|
G |
Fdps |
farnesyl diphosphate synthase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FDPS mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:188,403,595...188,413,219
Ensembl chr 2:188,392,858...188,413,219
|
|
G |
Fdx1 |
ferredoxin 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FDX1 mRNA |
CTD |
PMID:14729362 PMID:15336504 |
|
NCBI chr 8:56,373,729...56,393,199
Ensembl chr 8:56,373,723...56,393,233
|
|
G |
Fdxr |
ferredoxin reductase |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FDXR mRNA |
CTD |
PMID:12414654 PMID:27509014 |
|
NCBI chr10:103,817,724...103,826,413
Ensembl chr10:103,817,704...103,826,448
|
|
G |
Fen1 |
flap structure-specific endonuclease 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FEN1 mRNA |
CTD |
PMID:12414654 PMID:15336504 |
|
NCBI chr 1:226,251,516...226,256,160
Ensembl chr 1:226,251,518...226,255,886
|
|
G |
Fermt2 |
FERM domain containing kindlin 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FERMT2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr15:19,807,806...19,876,557
Ensembl chr15:19,807,808...19,876,408
|
|
G |
Fgg |
fibrinogen gamma chain |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FGG mRNA |
CTD |
PMID:12414654 |
|
NCBI chr 2:181,987,080...181,994,523
Ensembl chr 2:181,987,217...181,994,514
|
|
G |
Fh |
fumarate hydratase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FH mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:93,651,486...93,677,371
Ensembl chr13:93,651,484...93,677,377
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FHL1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr X:159,112,516...159,172,528
Ensembl chr X:159,112,880...159,172,524
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FHL2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 9:49,920,611...49,994,906
Ensembl chr 9:49,920,854...49,950,093
|
|
G |
Fhod3 |
formin homology 2 domain containing 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FHOD3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr18:16,650,786...17,332,209
Ensembl chr18:16,650,806...17,332,210
|
|
G |
Fibp |
FGF1 intracellular binding protein |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FIBP mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:220,840,078...220,844,412
Ensembl chr 1:220,840,118...220,844,405
|
|
G |
Fis1 |
fission, mitochondrial 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FIS1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr12:22,750,485...22,765,324
Ensembl chr12:22,750,485...22,765,308
|
|
G |
Fjx1 |
four-jointed box kinase 1 |
multiple interactions decreases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of FJX1 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of FJX1 mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of FJX1 mRNA; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of FJX1 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 3:92,288,818...92,290,919
Ensembl chr 3:92,288,818...92,290,919
|
|
G |
Fkbp1a |
FKBP prolyl isomerase 1A |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FKBP1A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:147,042,944...147,062,725
Ensembl chr 3:147,042,944...147,062,724
|
|
G |
Fkbp8 |
FKBP prolyl isomerase 8 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FKBP8 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr16:20,645,956...20,652,890
Ensembl chr16:20,645,957...20,652,889
|
|
G |
Flnb |
filamin B |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FLNB mRNA |
CTD |
PMID:15336504 |
|
NCBI chr15:18,750,152...18,883,019
Ensembl chr15:18,750,118...18,883,005
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FMO1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr13:80,712,885...80,745,095
Ensembl chr13:80,712,882...80,745,347
|
|
G |
Fn1 |
fibronectin 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FN1 mRNA |
CTD |
PMID:15963989 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
Folr1 |
folate receptor alpha |
increases expression decreases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FOLR1 mRNA tert-Butylhydroperoxide results in decreased expression of FOLR1 mRNA |
CTD |
PMID:14729362 PMID:15003993 PMID:22956110 |
|
NCBI chr 1:166,934,457...166,945,864
Ensembl chr 1:166,934,460...166,943,592
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression increases methylation increases expression multiple interactions |
ISO |
tert-Butylhydroperoxide results in decreased expression of FOS mRNA tert-Butylhydroperoxide results in increased methylation of FOS gene tert-Butylhydroperoxide results in increased expression of FOS mRNA CAT protein inhibits the reaction [tert-Butylhydroperoxide results in increased expression of FOS mRNA]; Glutathione inhibits the reaction [tert-Butylhydroperoxide results in increased expression of FOS mRNA]; Thiourea inhibits the reaction [tert-Butylhydroperoxide results in increased expression of FOS mRNA] |
CTD |
PMID:12419474 PMID:15105052 PMID:27509014 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FOSL1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
|
|
G |
Foxd1 |
forkhead box D1 |
decreases expression increases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FOXD1 mRNA tert-Butylhydroperoxide results in increased expression of FOXD1 mRNA |
CTD |
PMID:15003993 PMID:15336504 |
|
NCBI chr 2:28,460,068...28,462,488
Ensembl chr 2:28,460,068...28,462,488
|
|
G |
Foxm1 |
forkhead box M1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FOXM1 mRNA |
CTD |
PMID:12414654 PMID:15336504 |
|
NCBI chr 4:161,685,236...161,697,633
Ensembl chr 4:161,685,258...161,696,305
|
|
G |
Ftl1 |
ferritin light chain 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FTL mRNA |
CTD |
PMID:12414654 PMID:15963989 |
|
NCBI chr 1:101,448,190...101,450,034
Ensembl chr 1:101,448,346...101,449,829
|
|
G |
Fubp1 |
far upstream element binding protein 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FUBP1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 2:257,425,676...257,452,745
Ensembl chr 2:257,425,679...257,449,568
|
|
G |
Fxyd5 |
FXYD domain-containing ion transport regulator 5 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of FXYD5 mRNA |
CTD |
PMID:14729362 PMID:15003993 PMID:15336504 |
|
NCBI chr 1:89,464,853...89,474,450
Ensembl chr 1:89,464,860...89,474,252
|
|
G |
Fyco1 |
FYVE and coiled-coil domain autophagy adaptor 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FYCO1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 8:132,844,042...132,910,905
Ensembl chr 8:132,844,043...132,911,193
|
|
G |
Fzd1 |
frizzled class receptor 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FZD1 mRNA |
CTD |
PMID:29432895 |
|
NCBI chr 4:26,470,864...26,475,262
Ensembl chr 4:26,470,864...26,475,262
|
|
G |
Fzr1 |
fizzy and cell division cycle 20 related 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of FZR1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:11,201,690...11,213,614
Ensembl chr 7:11,201,690...11,213,613
|
|
G |
G0s2 |
G0/G1switch 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of G0S2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr13:112,004,140...112,005,052
Ensembl chr13:112,004,140...112,005,052
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases activity increases activity |
ISO EXP |
tert-Butylhydroperoxide results in decreased activity of G6PD protein tert-Butylhydroperoxide results in increased activity of G6PD protein |
CTD |
PMID:12628296 PMID:15336504 PMID:16928893 |
|
NCBI chr X:156,274,800...156,293,935
Ensembl chr X:156,274,800...156,293,926
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
decreases expression affects expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GADD45B mRNA tert-Butylhydroperoxide affects the expression of GADD45B mRNA |
CTD |
PMID:15336504 PMID:23410634 |
|
NCBI chr 7:11,646,283...11,648,338
Ensembl chr 7:11,646,269...11,648,322
|
|
G |
Gak |
cyclin G associated kinase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GAK mRNA |
CTD |
PMID:12419474 |
|
NCBI chr14:2,100,104...2,174,332
Ensembl chr14:2,100,106...2,174,318
|
|
G |
Galm |
galactose mutarotase |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GALM mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 6:2,808,988...2,860,742
Ensembl chr 6:2,808,841...2,860,744
|
|
G |
Galns |
galactosamine (N-acetyl)-6-sulfatase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GALNS mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:55,391,004...55,423,328
Ensembl chr19:55,389,462...55,423,150
|
|
G |
Galnt1 |
polypeptide N-acetylgalactosaminyltransferase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GALNT1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr18:16,141,062...16,187,271
Ensembl chr18:16,146,447...16,185,496
|
|
G |
Galnt3 |
polypeptide N-acetylgalactosaminyltransferase 3 |
increases methylation decreases methylation |
ISO |
tert-Butylhydroperoxide results in increased methylation of GALNT3 intron tert-Butylhydroperoxide results in decreased methylation of GALNT3 intron |
CTD |
PMID:29432895 |
|
NCBI chr 3:52,174,469...52,212,395
Ensembl chr 3:52,175,547...52,212,412
|
|
G |
Galnt6 |
polypeptide N-acetylgalactosaminyltransferase 6 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GALNT6 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:142,322,172...142,364,281
Ensembl chr 7:142,322,172...142,352,382
|
|
G |
Ganab |
glucosidase II alpha subunit |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GANAB mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:225,096,558...225,116,384
Ensembl chr 1:225,096,598...225,116,378
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GAPDH protein |
CTD |
PMID:11295360 |
|
NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
|
|
G |
Gars |
glycyl-tRNA synthetase |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GARS mRNA |
CTD |
PMID:15003993 |
|
NCBI chr 4:85,235,122...85,276,085
Ensembl chr 4:85,235,172...85,276,044
|
|
G |
Gas2 |
growth arrest-specific 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GAS2 mRNA |
CTD |
PMID:14729362 |
|
NCBI chr 1:107,234,389...107,363,624
Ensembl chr 1:107,262,659...107,363,788
|
|
G |
Gas2l1 |
growth arrest-specific 2 like 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GAS2L1 mRNA |
CTD |
PMID:29432895 |
|
NCBI chr14:85,308,443...85,318,475
Ensembl chr14:85,308,443...85,318,194
|
|
G |
Gata6 |
GATA binding protein 6 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GATA6 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr18:2,415,821...2,447,087
Ensembl chr18:2,416,552...2,446,338
|
|
G |
Gatd3a |
glutamine amidotransferase like class 1 domain containing 3A |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GATD3A mRNA |
CTD |
PMID:15336504 |
|
NCBI chr20:11,244,353...11,252,450
Ensembl chr20:11,244,353...11,252,449
|
|
G |
Gbp2 |
guanylate binding protein 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GBP2 mRNA |
CTD |
PMID:14729362 PMID:15003993 |
|
NCBI chr 2:248,276,795...248,293,784
Ensembl chr 2:248,276,709...248,293,784
|
|
G |
Gchfr |
GTP cyclohydrolase I feedback regulator |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GCHFR mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 3:110,975,923...110,979,957
Ensembl chr 3:110,975,923...110,979,957
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions decreases expression increases expression decreases response to substance |
ISO EXP |
[Linoleic Acids, Conjugated results in increased activity of GCLC protein] which results in decreased susceptibility to tert-Butylhydroperoxide tert-Butylhydroperoxide results in decreased expression of GCLC mRNA tert-Butylhydroperoxide results in increased expression of GCLC mRNA [Apigenin results in increased expression of GCLC mRNA] which results in decreased susceptibility to tert-Butylhydroperoxide; [Buthionine Sulfoximine results in decreased activity of [GCLC protein binds to GCLM protein]] inhibits the reaction [chrysin inhibits the reaction [tert-Butylhydroperoxide results in increased chemical synthesis of Reactive Oxygen Species]]; [chrysin results in increased expression of GCLC mRNA] which results in decreased susceptibility to tert-Butylhydroperoxide; [Luteolin results in increased expression of GCLC mRNA] which results in decreased susceptibility to tert-Butylhydroperoxide GCLC protein results in decreased susceptibility to tert-Butylhydroperoxide |
CTD |
PMID:12425961 PMID:17092368 PMID:22864849 PMID:23410634 PMID:27509014 PMID:30547568 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions increases expression |
EXP ISO |
[Apigenin results in increased expression of GCLM mRNA] which results in decreased susceptibility to tert-Butylhydroperoxide; [Buthionine Sulfoximine results in decreased activity of [GCLC protein binds to GCLM protein]] inhibits the reaction [chrysin inhibits the reaction [tert-Butylhydroperoxide results in increased chemical synthesis of Reactive Oxygen Species]]; [chrysin results in increased expression of GCLM mRNA] which results in decreased susceptibility to tert-Butylhydroperoxide tert-Butylhydroperoxide results in increased expression of GCLM mRNA |
CTD |
PMID:12414654 PMID:22864849 PMID:23410634 PMID:27509014 PMID:30547568 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gcnt1 |
glucosaminyl (N-acetyl) transferase 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GCNT1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:236,547,729...236,585,037
Ensembl chr 1:236,580,034...236,585,035
|
|
G |
Gcnt3 |
glucosaminyl (N-acetyl) transferase 3, mucin type |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GCNT3 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 8:76,449,078...76,459,431
Ensembl chr 8:76,449,081...76,452,554
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GDF15 mRNA |
CTD |
PMID:12414654 |
|
NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
|
|
G |
Gdpd5 |
glycerophosphodiester phosphodiesterase domain containing 5 |
affects expression |
ISO |
tert-Butylhydroperoxide affects the expression of GDPD5 mRNA |
CTD |
PMID:23410634 |
|
NCBI chr 1:164,337,176...164,418,056
Ensembl chr 1:164,380,577...164,418,593
|
|
G |
Gem |
GTP binding protein overexpressed in skeletal muscle |
multiple interactions increases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of GEM mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of GEM mRNA; [troglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of GEM mRNA; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of GEM mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 5:25,339,479...25,353,661
Ensembl chr 5:25,349,928...25,353,661
|
|
G |
Gemin4 |
gem (nuclear organelle) associated protein 4 |
multiple interactions decreases expression |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of GEMIN4 mRNA; [rosiglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of GEMIN4 mRNA; troglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of GEMIN4 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr10:64,364,808...64,375,885
Ensembl chr10:64,368,809...64,375,816
|
|
G |
Gfap |
glial fibrillary acidic protein |
decreases expression increases expression |
EXP |
tert-Butylhydroperoxide results in decreased expression of GFAP protein tert-Butylhydroperoxide results in increased expression of GFAP protein |
CTD |
PMID:24394546 |
|
NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
|
|
G |
Gfer |
growth factor, augmenter of liver regeneration |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GFER mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:14,059,347...14,061,703
Ensembl chr10:14,059,347...14,061,703
|
|
G |
Gfpt2 |
glutamine-fructose-6-phosphate transaminase 2 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GFPT2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:35,279,237...35,325,506
Ensembl chr10:35,279,236...35,325,508
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GFRA1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:279,203,046...279,572,789
|
|
G |
Gins2 |
GINS complex subunit 2 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GINS2 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:54,151,048...54,163,701
Ensembl chr19:54,151,048...54,163,608
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
decreases expression decreases response to substance |
ISO |
tert-Butylhydroperoxide results in decreased expression of GJA1 mRNA; tert-Butylhydroperoxide results in decreased expression of GJA1 protein GJA1 protein results in decreased susceptibility to tert-Butylhydroperoxide |
CTD |
PMID:15336504 PMID:18235030 |
|
NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
decreases response to substance |
ISO |
GJB2 protein results in decreased susceptibility to tert-Butylhydroperoxide |
CTD |
PMID:18235030 |
|
NCBI chr15:37,377,313...37,394,494
Ensembl chr15:37,377,316...37,383,277
|
|
G |
Gla |
galactosidase, alpha |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GLA mRNA |
CTD |
PMID:14729362 |
|
NCBI chr X:105,405,915...105,417,331
Ensembl chr X:105,406,792...105,417,323
|
|
G |
Glg1 |
golgi glycoprotein 1 |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GLG1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr19:42,983,879...43,088,074
Ensembl chr19:42,983,869...43,090,841
|
|
G |
Glipr1 |
GLI pathogenesis-related 1 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GLIPR1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 7:54,767,828...54,778,823
Ensembl chr 7:54,767,827...54,778,848
|
|
G |
Glod4 |
glyoxalase domain containing 4 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GLOD4 mRNA |
CTD |
PMID:15003993 |
|
NCBI chr10:64,379,922...64,398,263
Ensembl chr10:64,379,921...64,398,294
|
|
G |
Glrx |
glutaredoxin |
multiple interactions increases expression |
EXP ISO |
[GLRX protein co-treated with Glutathione] inhibits the reaction [tert-Butylhydroperoxide results in decreased activity of OGDH protein] tert-Butylhydroperoxide results in increased expression of GLRX mRNA |
CTD |
PMID:12414654 PMID:12680778 |
|
NCBI chr 2:2,606,032...2,615,944
Ensembl chr 2:2,605,996...2,615,944
|
|
G |
Glrx3 |
glutaredoxin 3 |
increases expression |
ISO |
tert-Butylhydroperoxide results in increased expression of GLRX3 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr 1:209,768,696...209,799,912
Ensembl chr 1:209,768,696...209,799,903
|
|
G |
Glyr1 |
glyoxylate reductase 1 homolog |
decreases expression |
ISO |
tert-Butylhydroperoxide results in decreased expression of GLYR1 mRNA |
CTD |
PMID:15336504 |
|
NCBI chr10:10,725,830...10,759,471
Ensembl chr10:10,725,819...10,761,279
| |